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Abstract 
Multiple Sclerosis (MS) is one of the most prevalent neurodegenerative diseases for which a cure 
is not yet available. MS is a complex disease for numerous reasons; its etiology is unknown, the 
diagnosis is not exclusive, the disease course is unpredictable and therapeutic response varies 
from patient to patient. There are four established subtypes of MS, which are segregated based 
on different characteristics. Many environmental and genetic factors are considered to play a role 
in MS etiology, including viral infection, vitamin D deficiency, epigenetical changes and some 
genes.  
Despite the large body of diverse scientific knowledge, from laboratory findings to clinical trials, 
no integrated model which portrays the underlying mechanisms of the disease state of MS is 
available. Contemporary therapies only provide reduction in the severity of the disease, and there 
is an unmet need of efficient drugs. The present thesis provides a knowledge-based rationale to 
model MS disease mechanisms and identify potential drug candidates by using systems biology 
approaches. Systems biology is an emerging field which utilizes the computational methods to 
integrate datasets of various granularities and simulate the disease outcome. It provides a 
framework to model molecular dynamics with their precise interaction and contextual details. 
The proposed approaches were used to extract knowledge from literature by state of the art text 
mining technologies, integrate it with proprietary data using semantic platforms, and build 
different models (molecular interactions map, agent based models to simulate disease outcome, 
and MS disease progression model with respect to time). For better information representation, 
disease ontology was also developed and a methodology of automatic enrichment was derived. 
The models provide an insight into the disease, and several pathways were explored by 
combining the therapeutics and the disease-specific prescriptions. The approaches and models 
developed in this work resulted in the identification of novel drug candidates that are backed up 
by existing experimental and clinical knowledge.  
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Glossary 
   
CellDesigner: CellDesigner [1] is a state-of-the-art structured diagram editor for drawing gene-
regulatory and biochemical networks. Its intuitive user interface helps draw diagrams in rich 
graphical representation with personalized design. Networks are constructed based on a state 
transition diagram proposed by Kitano et al. [2]. 
DrugBank: The DrugBank database [3] is a comprehensive online drug database. It contains 
detailed information about drugs and drug targets. Due to its extensive descriptions, it is 
considered as drug encyclopedia. DrugBank contains almost 10,000 drug entries and each one of 
them contains more than 200 data field. It is widely used by scientists, students and the general 
public. 
Ingenuity Pathway Analysis: Ingenuity Pathway Analysis (IPA) [4] is a life science knowledge 
base with powerful analytical and search tools. It integrates, stores and analyzes various types of 
biological data and help users identify new targets or candidate biomarkers. IPA has broadly 
been adopted by the life science research community and is cited in thousands of articles. 
KNIME: KNIME [5] is an open source, easy to use graphical user interface workbench for 
different data analytics processes. It provides a broad range of nodes and plug-ins to connect to 
data preprocessing, connecting to web services, run scripts and execute external applications 
within the workbench. 
Luxid: Luxid [6] is a commercial text mining system. It allows to mine text from various sources 
and with different skill cartridges (dictionaries) or patterns. The system also has ontology 
manager and semantic content enrichment features. The workflow option allows automation of 
certain tasks thus making it one of the favorite tools of text mining community.  
MediaWiki: MediaWiki [7] is a open source, free software written in PHP. It was developed for 
Wikipedia but now available for any other use. There are several wiki websites running based on 
MediaWiki. The organization which owns MediaWiki is WikiMedia Foundation. MediaWiki has 
large variety extensions which extend its functionality. It is interoperable, robust and very stable. 
MIRIAM: Minimum Information Required in the Annotation of Models (MIRIAM) [8] is a 
standardized set of metadata developed by the SBML community to facilitate the unified 
curation process of biological systems. The set of guidelines can be used with any structured 
format, allowing different groups to collaborate and share resulting models. 
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MySQL: MySQL [9] is an open source relational database management system (RDBMS) based 
on Structured Query Language (SQL). It is owned by Oracle Corporation. 
Netlogo Language: NetLogo [10] is a programming language and integrated modeling suite 
totally oriented and devoted to agent-based modeling. It is free, open source, and developed in 
Java by Uri Wilensky in 1999 and it has been continuously updated ever since. It features an 
extensive documentation, multiple tutorials and a worldwide community that furnishes great 
support. NetLogo represents a good choice to simulate multi-agents, networks and complex 
dynamical systems. Many scientific articles have been published using NetLogo. 
OntoFast: OntoFast [11] is an application that speeds up the development of new ontologies. It 
provides an easy to use and convenient interface that facilitates to build an ontology with 
associated metadata in short time. The output of the program can be easily opened and then used 
into a standard ontology editor like Protégé.  
Protégé: Protégé [12] is a free, open-source ontology editor. It was developed by the Stanford 
Center for Biomedical Informatics Research. Protégé provides a suite of tools to develop 
ontologies, domain models, and knowledge-based applications. It has many plug-ins which 
extend its functionality.  
SBML2SMW: SBML2SMW [13] is CellDesigner plug-in that stores CellDesigner models in a 
Semantic MediaWiki format. This plug-in allows extracting CellDesigner model information, 
storing this information to a Semantic Mediawiki server and context-sensitive restoring and 
integration of this information in a CellDesigner model. The application consists of two parts: 
The CellDesigner plug-in itself which directly communicates with the CellDesigner and so has 
access to the CellDesigner models and the Translation Server which receives the extracted 
information and translates it into Semantic Mediawiki syntax and stores it there. 
SCAIView: SCAIView [14] is a semantic search engine for life sciences. It processes large 
volume of text to facilitate the quick identification life science concepts. The backend system 
works on technologies such as text mining and semantic web to provide a refine search results.  
UMLS: Unified Medical Language Systems (UMLS) [15] is a very large repository of medical 
concepts which integrates and streamlines many health vocabularies to enable interoperability 
among them. UMLS has more than 100 source vocabularies and it has been reported that the 
2009AB release of the UMLS Metathesaurus contained 2,120,271 biomedical concepts and 
5,305,932 unique terms [16]. Two areas of its usage are in electronic health records software 
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development and by health-related language translators. UMLS deals with the complexity of 
different biomedical concepts by assigning a unique identifier to them, called a Concept Unique 
Identifier (CUI). 
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1. Chapter 1: Introduction to Scientific Challenges 
1.1 Complexity of the human brain: 
The human brain is who we are; it is our core, it makes us, it controls all of our physical systems, 
and consciousness. It can be considered as a very advanced-level programming language, as by 
definition a programming language is a formal set of words designed to communicate 
instructions to a system [17]. The brain communicates instructions to different systems of the 
body and reprograms instructions in real time, based on the feedback. It is a processor which 
takes input, processes it, and delivers output. It stores our short and long term memories. It 
receives feedback, sends orders, and decides the actions based on the collected information. 
Multiple sensors bring information to the brain so it can make decisions about anything which 
happens around it. The brain remains in darkness but still makes us feel brightness. It is in a 
silent place but allows us to hear loudness. It allows us to taste, smell, and be happy during 
certain events, or performing certain actions. Furthermore, the brain does not need eyes to let you 
see; for example, dreams can be experienced and visualized whilst the eyes are closed. In fact, 
we live our life in the brain; clinical death is only announced when the brain ceases to function. 
In addition, the brain is one of the few organs which remains functional all the time and does not 
rest like any other body part. It is only our brain which distinguishes us from other animals; as 
we extend the possibilities and solve the mysteries of universe.  
The human brain is considered to be the most complicated structure known in the universe and 
the most complex organ of the body. It has been shown that the human brain has approximately 
86 billion neurons and almost the same number of non-neuronal glial cells [18], although only 
302 neurons are required for a living organism with a functional nervous system (C. elegans have 
only 302) [19]. Each neuron can be connected to as many as 10,000 others, thus connections 
could potentially reach up to 100 trillion. The existence and functionality of the plethora of 
molecules in the human brain are still ambiguous and largely unknown [20]. The enormous 
numbers of cells and connections make it further difficult organ to study.  
Since the human brain directs all the other parts of the body to react to different environmental 
stimuli, the interplay between environment and genetic information is crucial for brain activity. 
Therefore, the role of environment is crucial to its well-being. The interaction of both of these 
factors is called gene-environment interaction. One interesting and simple example of the role of 
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the environment in our health is the risk of skin cancer in fair skinned people being significantly 
higher than that of dark skinned people, through prolonged exposure to sunlight [21]. In the 
following chapters, the crucial role of environmental factors (specifically vitamin D deficiency) 
in some aspects of brain diseases as well as in brain deterioration will be discussed. Often the 
environmental role is in chronological order as most of victims are elderly people.  
Neurodegenerative diseases are characterized by the degeneration of cells in the nervous system. 
It is a broad term used to define different diseases which have similar characteristics; they act on 
neurons to degrade or destroy them. Almost all of the neurodegenerative diseases impair brain 
functionality and they are complicated to treat because of our limited knowledge of brain 
functions. Neurodegenerative diseases are an area of major concern to healthcare providers, since 
they are a burden on the social system due to the occurred expenses during treatment, and they 
make patients handicapped and dependent in a chronic fashion. Many initiatives have been 
introduced to understand brain functionality and to better cope with neurodegenerative diseases. 
Human Brain Project [22], BrainInitiative [23], Allen Brain Atlas [24], Blue Brain Project [25], 
and BrainMaps [26] are a few among countless projects. 
The ongoing research and number of publications associated with neurodegenerative diseases are 
increasing at a higher rate (Figure 1.1) but the need for new therapies for different brain 
disorders remains largely unmet. Due to the brain’s complexity, there have been a number of 
failed attempts to create a drug which can combat the diseases impacting the brain. Many tests 
show promising results in model organisms but not in humans. Furthermore, the model 
organisms only represent few aspects of the human brain, thus limiting the scope of research and 
drug development.  
1
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Figure 1.1: Publications record indexed in PubMed with the Mesh term “Neurodegenerative Diseases” over time. 
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The massive amount of scientific literature available for different brain disorders is not useful 
enough to find a cure of neurodegenerative diseases. The quest to transform “data into 
knowledge and wisdom” could be advanced by changing the ways we look into and interpret the 
literature. The following chapters will demonstrate the use of various knowledge management 
approaches, in order to tackle the daunting task of finding hidden pearls of knowledge associated 
with a specific disease, namely Multiple Sclerosis. Although these methods will be applied here 
to Multiple Sclerosis, they can be applied to any other neurodegenerative disease.  
1.2 Research motivation: 
After the successful eradication of common infectious diseases, the new battleground for 
researchers is the study of diseases whose causative agents are either unknown or involve more 
than one factor. Brain diseases are some of the most challenging due to the complexity of the 
organ, its isolation from the environment, and the roles played by genetic and environmental 
factors in these diseases. Most of the diseases happen to occur in a chronological order 
demonstrating the role of genetic and environmental factors’ interplay. In addition to brain being 
complex, the diseases are prone to be more difficult to study as the brain is not exposed directly 
to the environment. Therefore, special equipments are needed to investigate them.  
Despite the modern technology and discovery of advanced molecular biology techniques, 
researchers are still struggling to find a cure for neurodegenerative diseases. One of the major 
neurological diseases which remains incurable is Multiple Sclerosis (MS). MS is one of the most 
common disorders of central nervous system, affecting between an estimated 2.3 to 2.5 million 
people worldwide [27].  
MS starts at an early age, renders people handicapped through lifelong progression of the 
disease, and many complications are associated with it. The major consequences of having MS 
are neuronal damage and the unpredictable course as the disease progresses. It causes significant 
disability in patients and has a considerable influence on the personal life of the patient, with 
regards to social impact, cost, and quality of life. The cost of living with MS is significantly 
higher than other brain diseases. Figure 1.2 shows the comparative survey of costs associated 
with different disorders in European countries.  
 
 
1
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Figure 1.2: Cost per person with a disorder of the brain in different European countries. Purple colour shows the data of Multiple Sclerosis and it can be seen 
that in most of the European countries the cost of MS treatment is higher than any other diseases. edited version of [10]. 
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The incurred costs of MS treatment are not only higher than any other disease, but indirect costs 
and other non-medical costs also make it one of the expensive diseases to treat (Figure 1.3). 
 
 
 
 
2
1
 
  
Figure 1.3: Non-medical/indirect cost per person (in €) of different brain disorders comparison, taken from [10]. 
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1.3 Research goal: 
The goal of the research work is to foster drug discovery by: 
• Extracting relevant information from public and proprietary data (e.g. clinical 
trials), in order to unravel the hidden pieces of knowledge and intertwine them; 
this could reveal the underlying mechanism of different disease phenomena. 
• Modeling knowledge based on molecular interaction maps and developing models 
of MS in time dependent manner with biomarkers involved in the different stages 
of the disease. 
• Simulating different aspects of MS disease by using various modeling approaches 
which could reproduce similar patient outcomes after an in-silico experiment has 
been performed. 
• Increasing knowledge reach by improving current tool sets. This includes gaining 
access to datasets which are available in languages other than English. 
1.4 Thesis outline: 
Following is a brief outline of the upcoming chapters and respective papers linked to them.  
Chapter 2 discusses about the complexity of MS, risk factors, processes involved in the disease, 
disease subtypes, biomarkers associated with the disease, and available therapies currently in the 
market.   
Chapter 3 focuses on various systems biological approaches to model MS, their limitations, and 
their role in drug discovery. Molecular interaction maps, systems biology languages, and agent 
based modeling are discussed in details. Systemic review of the current literature is also 
discussed.  
Chapter 4 focuses on the methodology part of all the work done in this thesis. In this chapter, 
various approaches about information retrieval and modeling have been described. The 
methodology part was divided into two parts; first part discusses the foundational work for 
developing the MS models and all information retrieval work while second part focuses on the 
modeling work. 
Chapter 5 discusses the results and findings of the thesis. The main outcomes of the thesis are: 
• A molecular interaction model of the MS disease 
• An automated methodology to enriching and/or translating any ontology 
23 
 
• A disease specific ontology which has been translated and used to mine Electronic 
health records 
• Time series patterns of MS progression and speculation of combination therapy 
Chapter 6 discusses the forthcoming possibilities of the work and limitations faced during the 
work. It also describes the outcome of the research and their application. 
In the following section the outline of thesis’ result section is given with all the publications 
under relevant topics. In addition, a paragraph of my contribution is also provided. 
Information retrieval and representation: 
• Ontology Development [28]: 
o This paper describes the work of processing large amount of information and 
information representation. In order to retrieve useful information from scientific 
literature and electronic medical records (EMR) an ontology specific for Multiple 
Sclerosis (MS) has been developed. The paper relates to the goals mentioned in 
the first chapter “Extracting relevant information from public and proprietary 
data” and “Increasing knowledge reach by improving current tool sets”. The MS 
Ontology was created using scientific literature and expert review under the 
Protégé OWL environment. The MS Ontology was integrated with other 
ontologies and dictionaries (diseases/comorbidities, gene/protein, pathways, drug) 
into the text-mining tool SCAIView, a tool developed by Fraunhofer Institute for 
semantic search. MS ontology has also been used to analyze the EMRs from 624 
patients with MS in order to identify drug usage and comorbidities in MS. The 
challenges faced were that no structured knowledge was available about MS, and 
limited available tools to mine datasets available in languages other than English. 
The challenges were dealt by developing a disease specific ontology and a 
methodology to translate any ontology. 
o My contribution for the work was; collecting all the concepts, developing the 
structure of ontology, mapping the concepts to UMLS and MeSH, enriching the 
ontology with the synonyms, definitions and identifiers, and translating the 
ontology into Spanish so it can be used for Spanish EMR dataset shared by 
collaborators. 
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• Automated data retrieval from UMLS[29]: 
o This paper describes a methodology which enriches ontologies in significantly 
less time and with an automated way. This paper relates to the thesis because 
ontology enrichment was the foundation of ontology development and ontology 
was developed to have a unified source of knowledge for modeling the disease. 
One of the challenges faced during the ontology development was enriching the 
terms with relevant concepts. Ontology enrichment is a process of embedding 
metadata associated with concepts described in the ontology. Manual information 
retrieval and enrichment process is labor-intensive and time-consuming as each 
concept is unique and has domain specific meanings. An approach to deal with 
this problem is to have a unified resource and an automated solution. 
o My contribution for the work was; everything, namely; building the workflow, 
installing and configuring UMLS locally, automating the procedure, running the 
queries, testing the output, cleaning the output, and writing the publication. The 
second author only reviewed the publication and tested the system. 
 
• Automated Ontology Translation from UMLS:  
o Not published yet. 
o All the work done by me. 
 
• OntoFast [11]: 
o This publication describes a tool named OntoFast, which provides an easy to use 
interface for ontology development. Ontology development is a time-consuming 
task and with the help of this tool, ontology can be developed in few days. The 
challenge faced was the complex structure of OWL and the way it stores the 
embedded knowledge. The task of the tool development was completed after 
thorough research and investing some time.  
o My contribution for the work was; proposing the idea, monitoring the 
development, providing all the relevant knowledge, testing, exclusively using the 
tool, and writing the manuscript. 
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• Corpus generation from web to analysis the content and applying NLP tools [30]: 
o This publication describes the approach of collecting clean dataset from public 
domains. This also relates to the goals mentioned in the first chapter “Extracting 
relevant information from public and proprietary data”. The challenge faced was 
that required data was not easily accessible and concealed under many layers. The 
challenge was dealt by providing a methodology which can process the data under 
several layers of web pages and it can be applied to any other website.  
o My contribution for the work; I am the only author. 
 
• SBML2SMW, Transforming Systems Biology knowledge into MediaWiki Pages [13]: 
o This publication[13] describes about the connected framework established for 
integrating, storing and reusing the scattered knowledge of different domains e.g. 
Systems biology tools, Text mining systems, and semantic web applications. This 
relates to one of the goals mentioned in the first chapter, “Extracting relevant 
information from public and proprietary data”. The challenges faced were that 
different domains of knowledge provide different data format and often the 
outputs are not interoperable. We linked the two very popular technologies, 
MediaWiki and Systems Biology Markup Language by developing a free plug-in 
which bridges the gap between them and increases knowledge reach. 
o My contribution for the work was; proposing the idea, monitoring the 
development, testing, exclusively using the system, and writing the manuscript. 
Modeling of MS disease: 
• Molecular interaction map of MS [31]: 
o Molecular interaction maps (MIMs) are interaction maps of molecules that are 
involved in a biological function. The map of MS is published at Payao website 
[31]. MS map is one of its kind as it contains text extracted from scientific 
literature under each edge with PMIDs. The map was developed by manually 
reading research papers. Challenges were that manual reading is time-consuming 
and map visualization is an issue after map has developed to a certain extent. 
Challenges were dealt by using various semantic software and running queries to 
retrieve the required knowledge.  
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o My contribution for the work was; I am the only author.  
 
• Time series of MS disease progression and combinatorial therapy: 
o Not published yet. 
o All the work done by me.  
 
• Agent based model of Treg-Teff interplay and its role in RRMS:  The Model and 
Simulation [32]: 
o This paper describes the interplay between Treg-Teff and the role in relapsing 
remitting subtype of MS. The work was done by using Agent based modeling 
technique and NetLogo application was used. The model shows results obtained 
from eight randomly chosen individuals. They were genetically predisposed 
mimicking absence and presence of malfunctions of Teff-Treg cross-balancing 
mechanism. The presented model allows to capture the essential dynamics of 
relapsing-remitting MS despite its simplicity. It gave useful insights that support 
the hypothesis of a breakdown of Teff-Treg cross balancing mechanisms. 
o My contribution for the work was; shared the knowledge about MS and review 
the publication. 
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2 Chapter 2: Complex Biological Mechanisms Underlying Multiple 
Sclerosis  
2.1 Multiple sclerosis: 
Multiple Sclerosis (MS) is one of the most common chronic inflammatory diseases which affects 
the central nervous system and causes its deterioration. MS is also known as disseminated 
sclerosis or encephalomyelitis disseminata. It usually begins between age 20 to 50, and the ratio 
between males and females is 1:2 [33]. It causes sclerosis, which is a Greek word meaning 
“hardening” and the term refers to myelin sheath hardening or the formation of lesions on the 
myelin. In this disease, lesions mostly occur in the white matter of the brain and spinal cord. MS 
is a neurodegenerative disease which causes hindrance in axon communication by injuring the 
myelin sheath, which results in different signs and symptoms, including physiological and 
mental problems [34]. Besides the patient’s personal life dilemma, MS also causes a significant 
social burden on the healthcare system. It has been estimated that between 2 to 2.5 million 
people are affected by MS, and the cost associated with it is significantly higher as compared to 
other neurological diseases. This higher cost is mostly due to the chronic nature of the disease. It 
is more prevalent in Europe, Canada, and the US as compared to rest of the world. Table 2.1 
shows the natural history of MS, percentage of women affected, and onset age.  
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 Italy Canada France Canada Sweden USA 
Number of patients 1463 2837 1844 1099 255 201 
% Women 67.2% 70.4% 64.4% 65.7% 60.0% 69.7% 
Onset age (all) 
28.3 
years 
30.6 years 31.0 years 30.5 years – 31.2 years 
(standard deviation) (9.0) (10.0) (9.7) (9.9) – – 
< 15 years 3.8% – – – – – 
< 20 years 18.7% 9.6% 11.7% 12.0% – – 
> 40 years 11.6% 13.8% 20.6% 20.1% – – 
> 50 years 1.9% 4.7% 5.9% – – – 
Relapsing onset (%) 86.1% 87.6% 84.7% 81.2% 85.9% 94.5% 
Earliest onset – – 5 years – – 12 years 
Latest onset – – 62 years – – 58 years 
Mean age relapsing onset – – 29.5 years    
Mean age progression onset       
SPMS – 49.0 years 39.5 years 40.1 years – – 
PPMS – 41.0 years 39.3 years 38.6 years – – 
Time to EDSS = 4, median – – 8 years – – – 
Relapsing onset – – 11 years – – – 
Progressive onset – – 0 years – – – 
Time to EDSS=6, median – 28 years 14 years 15 years 18 years 26 years 
Relapsing onset – – 23 years – 23 years 28 years 
Progressive onset – – 7 years – 6 years 7 years 
Table 2.1: Summary of natural history of Multiple Sclerosis in different countries, edited version of [35]. 
 
MS is a complex disease for numerous reasons. Its etiology is unknown, the diagnosis is not 
exclusive, the disease course is unpredictable, and therapeutic response varies from patient to 
patient. The etiology of disease is still ambiguous despite the fact that the disease was firstly 
described in 1868 [36], and medical science has advanced significantly since then. There are 
many hypotheses about the brain regions mainly involved [37] and disease causation. Viral 
infections [38], epigenetical changes [39], mitochondrial defects [40], Vitamin D deficiency 
[41], and the role of genetics [42] have been proposed to play a role in disease etiology. The 
diagnosis is also very challenging; physicians must rule out other ailments by asking different 
questions and taking tests, as many other medical conditions share similar symptoms. Even the 
expert physicians can diagnose the disease correctly only 90-95 percent of the time [43]. There is 
no single test which can be conclusive about the diagnosis. The disease course of MS can be 
acute or chronic. As the disease is highly unpredictable, the victims normally do not know which 
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organ or system will be affected next. The disease course variation between individuals means 
that treatments may not affect all patients in a similar manner. This includes one of the most 
effective drugs against MS, interferon beta. 
What causes MS is still an open question, however there are factors which are considered 
relevant and are associated with the frequency of disease occurrence. The deficiency of Vitamin 
D, infection agents (specially Epstein-Barr Virus - EBV) and presence of some genetic variations 
are among them and are associated with a higher probability of disease occurrence [44]. It is also 
very interesting to know that MS is more common in people who live farther from the equator  
(Figure 2.1) than in those who live near it, though there are some exceptions [44][45]. Even 
though some genes show significant association with MS and females display a twofold 
increased likelihood to develop the disease, it is not considered to be a hereditary disease. The 
risk of having MS increases depending upon the closeness of the relation of the diseased person 
[46]. For instance, identical twins have a 30% probability of developing the disease if one of 
them is affected. In comparison, non-identical twins have only a 5% probability, and siblings 
have a probability of 2.5%. In addition, if both parents are affected, then the risk of having 
children with MS increases by 10 times compared to general population [33]. 
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Figure 2.1: Global distribution of MS prevalence. MS is more common in people who live farther from the equator, taken 
from [35]. 
2.1.1 Relapse and remission: 
Relapse is a term which defines a period of worsening of disease activity; it includes the 
development of new symptoms or reoccurrence of previous symptoms, with or without increased 
severity. Remission is defined as complete or partial recovery of the symptoms, following 
relapse. Some factors can halt or trigger a relapse, e.g. pregnancy. Relapse is less likely during 
the gravid vs. non gravid state, and is especially unlikely during the third trimester [47]. Factors 
which could increase the risk of having a relapse are infections and other ailments which include 
fever, cough, rhinorrhea, nausea, and diarrhea as symptoms [48–51]. 
2.2 Risk factors of multiple sclerosis:  
There are many risk factors associated with MS; some are proven to have a role in disease 
pathogenesis. Others are hypothesized but do not have sufficient data available to prove their 
significant influence on the disease etiology. Here we will discuss some of the factors as shown 
in the figure 2.2. 
The genes most commonly associated with MS are the HLA genes, a known fact for more than 
30 years [52]. Interestingly, it has been found recently that HLA genes have a role in Vitamin D 
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gene expression [53]. Furthermore, the same group of genes are also associated with other 
autoimmune diseases such as diabetes mellitus type 1 and systemic lupus erythematosus [52]. 
DR15 and DR6 have been found to be more consistent alleles in MS disease association [44]. On 
the contrary, some other alleles such as HLA-c554 and HLA-DRB1*11 have been shown to have 
a protective role [44]. In addition, HLA-DR15 occurrence within the Caucasian race also 
increases the likelihood of the disease.  There are also certain haplotypes which are linked to an 
increased likelihood of MS disease, e.g. IL7RA and IL2RA. Primary oligodendropathy and some 
of the single nucleotide polymorphisms (SNPs) are also linked with disease etiology [54,55]. 
Besides genetic predisposition, viral infections such as EBV also play an important role in MS 
prevalence. It has been documented that an early age infection of EBV has a protective role 
against the disease and late infection is considered as a risk factor. Individuals who have never 
been infected by EBV are at a reduced risk of getting MS as compared to those who got infected 
at younger age [44][56]. High Epstein–Barr nuclear antigen 1 (EBNA-1) titres are also 
considered as a risk factor in disease occurrence. The environment has also been considered to 
play a crucial role in MS disease etiology. Low exposure to sunlight (resulting low Vitamin D 
levels) and babies born in May are more prone to develop the disease as compared to babies born 
in November. It could be argued that it is also due to Vitamin D deficiency, as mother was less 
exposed to sunlight during pregnancy. Another important environmental factor is smoking, 
which is linked to an increase in the likelihood of disease.  
The following single molecules are considered to play a significant role in disease etiology, and 
there are certain drugs which target these molecules and suppress the disease. For example, 
VLA-4 is one of the molecules which is suggested to play a role in disease. It has been proven by 
the fact that the drug Natalizumab reduces disease severity by targeting it. Other molecules 
which are considered to have a role in the disease are IFN-y, IL-17A, IL-23, Osteopontin, 
Complement system and ROS.  
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Figure 2.2: An overview of different factors involved in MS. Risk factors on the left (pink) increase susceptibility (S) to 
disease likelihood (dashed line). Strong genetic components (G) and environmental factors are part of them. Suspects are 
entities which are thought to be overall deleterious. In the centre of the image, the damage in MS has been shown; red 
pointers show the points of attack i.e. myelin sheath, oligodendrocytes, axons and neurons. Guardians are entities which 
are thought to repair the damage. Protective factors (green) decrease susceptibility to the disease, edited version of [35]. 
  
2.3 The three pillars of MS disease: Demyelination, neurodegeneration and 
autoimmunity: 
2.3.1 Demyelination or myelin damage: 
Myelin damage (also known as demyelination) is a term used to define a condition when the 
myelin sheaths of the axons become damaged, and the electrical pulse is lost during 
transportation. Different patterns of myelin damage have been documented, e.g. myelin 
stripping, dissolution of myelin sheath by invasion of macrophages [57] and binding of myelin 
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fragments to vesicles of macrophages [58]. Demyelination causes signal deterioration and as a 
consequence, organs which are supposed to act on nerve signals stop responding. This can cause 
body systems to malfunction. This state has been considered as the disease onset, and is 
associated with relapsing remitting MS (RRMS).  
2.3.2 Neurodegeneration: 
Neurodegeneration is a broad term which describes the processes involved in the deterioration of 
the nervous system; it literally means nerves (neuro-) and destruction (-degeneration). 
Neurodegeneration in MS occurs when immune cells enter the CNS and cause neurotoxic 
effects. Lesion formation, which is a hallmark of MS, occurs when immune cells react with 
myelin protein [59,60] causing damage to nerve cells. There is a large body of literature 
available which supports the notion that neurodegeneration is a very important process in MS. 
Histological examination and postmortems of brains show the axonal damage and subsequent 
loss [61,62]. Progressive brain atrophy and reduction of N-Acetyl aspartic acid have also been 
documented extensively in MS [63,64]. In addition to neurodegeneration, it has been shown that 
immune cells also play a vital role in neuroprotection after entering the CNS [65,66]. It has been 
shown that there are two different mechanisms involved in neurodegeneration with respect to 
acute and chronic subtypes of MS. Acute MS is characterized by lesions infiltrated by 
macrophages and T-cells. In chronic MS, activated microglia cause axonal damage. The balance 
among different populations of T-helper cells could yield different outcomes in the disease; this 
concept is known as T-helper cell polarization. The concept as discussed in [67] suggests that 
TH1 and TH-17 are responsible for CNS inflammation and neurodegeneration,  while a sub-
population of T-helper cells known as TH2 cells seem to play a neuroprotective role. This 
hypothesis is supported by findings that Glatiramer Acetate and Statins promote TH2 
polarization [68,69] to reduce the severity of the disease. In addition to TH cell populations, 
macrophages also have a similar pattern which results in a different cellular phenotype 
population [70]. M1 macrophages are considered to have a pro-inflammatory role, contributing 
to tissue destruction, while M2 macrophages have an anti-inflammatory role, contributing to 
tissue repair. Interestingly, Glatiramer Acetate can induce a population shift towards M2 
phenotype in MS [71]. This implies that shifting cell phenotypes could be a possible treatment 
option for neurodegeneration.  
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2.3.3 Autoimmunity: 
MS is a disease of the immune system in which autoimmunity is believed to play a crucial role. 
One of the strongest supportive arguments of this notion is that in the animal disease model of 
MS, experimental autoimmune encephalomyelitis (EAE) has immunopathological processes in 
the CNS which exhibit many aspects of MS [72]. Further supportive arguments include the 
presence of auto-antibodies [73], auto-reactive T-cells [74], anti-MOG antibodies [75], and MHC 
class II complexes with MBP peptides on antigen- presenting cells in MS lesions [76]. In 
addition, nearly all of the therapeutic agents given to suppress the MS disease activity act to 
effectively suppress the immune system, or otherwise alter its function [77]. Many of the genes 
involved in MS are often associated with other autoimmune diseases, supporting the theory that 
it is an autoimmune disease (Figure 2.3) [78]. These findings suggest that the immune system 
plays an important role in disease pathogenesis; however, whether these immunological 
processes are the primary cause of the disease or the reactions of some other stimulus is yet to be 
understood.  
The primary players of the disease pathogenesis are the auto-reactive T-helper cells that attack 
the myelin basic protein (MBP) and cause damage to it. T-cells cross the blood-brain barrier via 
the adhesion molecules e.g. VLA-4. They become stimulated by antigen-presenting cells, release 
pro-inflammatory cytokines and cause demyelination along with B-Cells and macrophages [79–
82]. Viral infections are suspected to play a key role in the activation of the T-cells’ auto-
reactivity by a process called molecular mimicry. Molecular mimicry is defined as when an 
immune cell cannot differentiate between bodily molecules and foreign particles due to 
significant structural similarities in the peptide sequences. Many viruses are homologous MBP 
including adenovirus, herpes simplex virus (HSV) and Epstein-Barr virus (EBV) [83]. Among 
these EBV has been shown prominently to be associated with immune system modulation and is 
considered to be an important factor in MS pathogenesis [84]. Due to multiple mimicry 
possibilities and different pathways’ involvements, it has been challenging to identify a single 
causative agent of MS. It is also hypothesized that variations in MS disease phenotypes may be 
due to the different agents involved in the disease subtypes.  
 
35 
 
 
Figure 2.3: Venn diagram of genetic overlap among different autoimmune diseases: The external circle shows the number 
of shared genes between a disease and MS. The Internal circle shows the count of susceptible shared genes. Clockwise 
from upper right legends: T1D= Type 1 Diabetes, RA= Rheumatoid Arthritis, CU= Colitis Ulcerosa, T2D= Type 2 
Diabetes, MS= Multiple Sclerosis. Taken from [85]. 
 
2.4 Heterogeneity in MS: 
There are four major and established subtypes of MS, which are segregated based on different 
characteristics. MS commonly begins with RRMS and then progresses in severity. Clinically 
Isolated Syndrome (CIS) is also considered as a stage of the disease, but it will not be discussed 
here as some people who have experienced CIS may not develop MS [86]. Table 2.2 shows the 
characteristics of the different subtypes of the disease. 
 
 
 
Type Characteristics Frequency at Disease Onset 
RRMS  Clearly defined relapses followed by full or nearly full recovery of 
function. The disease does not progress in between attacks. 
~85% 
SPMS Initial course of relapsing–remitting that is followed by progression, 
with or without occasional relapses or plateaus in function. The 
disease progresses over time. 
~50% of people with RRMS 
will transition to SPMS within 
15 years from diagnosis 
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PPMS  Gradual but continual worsening over time; some fluctuations but no 
distinct relapses 
~10% 
PRMS  Progressive course marked by distinct relapses, with or without 
recovery. The disease continues to progress between attacks. 
5% 
Table 2.2: MS disease subtypes and their characteristics, edited version of [94]. 
2.4.1 Relapsing remitting multiple sclerosis: 
The standard description of Relapsing Remitting Multiple Sclerosis (RRMS) defined by 
clinicians [87] is as follows: 
RRMS: “Clearly defined relapses with full recovery or with sequelae and residual deficit upon 
recovery; periods between disease relapses characterized by a lack of disease progression.” 
RRMS is the most common form of MS. It accounts for nearly 85% of all MS  cases [88]. In this 
subtype of the disease, patients face recurring instances of relapses which fade away after some 
time. For most of the people this is the start of disease, as the diagnosis is usually made when the 
patient experiences something distressful like double vision, loss of balance or thinking 
problems. One of the hallmarks of this form of MS is that it does not progress between the 
attacks. Figure 2.4 shows the progress pattern in RRMS.  
 
 
Figure 2.4: Disease progression pattern in RRMS, number of percentage shows the frequency of disease subtype. 
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2.4.2 Secondary progressive multiple sclerosis: 
The standard description of Secondary Progressive Multiple Sclerosis (SPMS) defined by 
clinicians [87] is as follows: 
SPMS: “Initial RR disease course followed by progression with or without occasional relapses, 
minor remissions, and plateaus.” 
SPMS is considered as a severe form of RRMS; usually it follows after RRMS.  It develops after 
severe neurodegeneration and neuron loss, for which the CNS cannot compensate [89]. This state 
has been characterized by axonal degeneration as compared to RRMS which is considered to be 
inflammatory demyelination. In almost 50% RRMS cases, the disease changes course to SPMS 
within a decade of disease onset. 90% of RRMS cases change course to SPMS after 20-25 years 
[90–93]. Figure 2.5 shows the progress pattern in SPMS. 
 
Figure 2.5: Disease progression pattern in SPMS. ~50% of people with RRMS will transition to SPMS within 15 years 
from diagnosis. 
 
2.4.3 Primary progressive multiple sclerosis: 
The standard description of Primary Progressive Multiple Sclerosis (PPMS) defined by clinicians 
[87] is as follows: 
PPMS: “Disease progression from onset with occasional plateaus and temporary minor 
improvements allowed.” 
PPMS is characterized by progression without remission and relapse. It happens in almost 10-
15% of the total patients. Unlike other forms of MS, there are no drugs available to cope with 
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this subtype of MS. In this form of the disease, disability progresses without remission or 
improvement of the condition. This is the only form of MS in which there are no relapses. The 
age of its onset is also late as compared to RRMS (39 vs. 29 years). Another interesting fact is 
that the incidence of PPMS is almost equal in males and females [94].This suggests an etiology 
that is different from other forms of MS. Figure 2.6 shows the progress pattern in PPMS.  
 
Figure 2.6: Disease progression pattern in PPMS, number of percentage shows the frequency of disease subtype. 
 
2.4.4 Progressive relapsing multiple sclerosis: 
The standard description of Progressive Relapsing Multiple Sclerosis (PRMS) defined by 
clinicians [87] is as follows: 
PRMS: “progressive disease from onset, with clear acute relapses, with or without full recovery; 
periods between relapses characterized by continuing progression” [87]. 
PRMS is the least frequently occurring subtype of MS; it occurs in ~5% of the MS patients. Its 
distinct feature is disease worsening and progression with relapses. Figure 2.7 shows the 
progress pattern in PRMS.  
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Figure 2.7: Disease progression pattern in PRMS, number of percentage shows the frequency of disease subtype. 
 
Despite the variety of different disease subtypes with different phenotypes associated and the 
extensive study thereof, an underlying mechanism for any variation of MS has not been found. 
Treatment options for PPMS are therefore not available. The existence of different phenotypes 
implies that there are different underlying biomarkers, mechanisms, and different sets of 
molecules involved. Though scientists are aiming to personalize medicines based on the 
personalized genotypes of individuals, it is interesting to know that pathways involved in certain 
diseases subtypes are yet to be known. In next section we will discuss different types of 
biomarkers and MS biomarkers.  
2.5 Biomarkers of MS: 
A biomarker or biological marker is a measurable marker which indicates a biological state or 
condition. A classic example of a biomarker has been given as a laboratory parameter which can 
be used to help clinicians diagnose a disease and select appropriate treatment. The formal 
definition of a biomarker is as follows: 
“A characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological responses to a therapeutic intervention” 
[95]. Biomarkers are needed to distinguish different conditions in a biological system. Of the 
different types of biomarkers, the following four are the most commonly used.  
40 
 
A Prognostic biomarker helps to predict the disease course and its progression. It is a marker 
whose alteration or amount is measured or exists before the clinical end points of the disease 
outcome. 
A Predictive biomarker is also known as a response biomarker. It helps clinicians to propose 
and prescribe a therapeutic course for the disease.  By definition, it is a marker whose alteration 
or amount is measured or exists before the clinical end points of the treatment response. It is a 
marker whose alteration or amount predicts the response of a patient group to a treatment.  
A Diagnostic biomarker helps to distinguish between a healthy state and a diseased one. It is a 
marker that is altered, or whose amount is modulated between the healthy and the non-treated 
disease states or between responders and non-responders (within the same disease). It illustrates 
the altered state between the diseased patients and healthy controls.   
A Pharmacodynamic biomarker measures the treatment effects of a drug to help prescribe the 
right dosage. It is a marker whose alteration or the amount of modulation results from the effect 
of the studied compound/drug. 
Like any other neurodegenerative disease biomarkers, MS biomarkers play a crucial role in 
diagnosing the disease, predicting the disease course, segregating the patient based on 
therapeutic response and optimizing the dosage response. Biomarker discovery is an important 
factor in MS, as the disease is heterogeneous in its clinical manifestations; conditions vary from 
patient to patient. Different kinds of biomarkers have been discovered and can be categorized, 
for example, by type (DNA, proteins and mRNA etc) or by the processes they are involved in 
(demyelination, oxidative stress and remyelination). The genetic biomarker HLA is one of the 
biomarkers widely accepted and associated with MS. It has been shown that two different types 
of HLA molecules exert different functions in MS. While soluble HLA-I has a role in 
neurological disorders and its presence in cerebrospinal fluid is linked with an increase in disease 
activity, soluble HLA-G is found to play a role in remission of disease [96–98]. One of the best 
known biomarkers for MS is the occurrence of Oligoclonal bands (OCBs) in cerebrospinal fluid, 
specifically increased level of IgG index [99]. OCBs are considered as a prognostic biomarker 
with higher specificity and sensitivity. It has been shown that OCBs are key indicators for the 
conversion of a clinically isolated syndrome into RRMS [100,101]. In addition, the presence of 
IgM OCBs has been associated with an aggressive disease course [102,103]. Besides molecular 
markers, there are many imaging biomarkers associated with MS which are considered as 
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authentic prognostic biomarkers; for example, the existence of black holes, the volume of T1 
,T2, and gadolinium-enhancing lesions [99,104]. 
 
Category Biomarkers 
Diagnostic biomarkers IgG oligoclonal bands; aquaporin-4 antibodies; heat-shock proteins 
Predictive biomarkers  
IgG and IgM oligoclonal bands; anti-MBP and anti-MOG antibodies; CHI3L1; Fetuin-
A; TOB1; anti-EBNA1 
    
Process-specific 
biomarkers   
1. Inflammation  
 
Cytokines; chemokines; adhesion molecules; MMPs; osteopontin; sHLA-I and sHLA-
II 
2. Demyelination  MBP and degradation products; CNPase; 7-oxygenated steroids 
3. Oxidative stress  NO and metabolites 
4. Glial activation  S100b; GFAP 
5. Remyelination/repair  NCAM; CNTF; BDNF; NGF; Nogo-A 
6. Neuroaxonal damage  NSE; Nf and anti-Nf antibodies; tau; NAA 
Table 2.3: Proposed molecular biomarkers associated with different phenotypes and disease mechanism, edited version of 
[105]. MOG: myelin oligodendrocyte glycoprotein; MBP: myelin basic protein; CHI3L1: chitinase 3-like 1; TOB1: 
transducer of ERBB2, 1; EBNA: nuclear antigen 1 of the Epstein–Barr virus; MMPs: matrix metalloproteinases; sHLA-I 
and sHLA-II: soluble HLA class I and II; CNPase: 2’:3’-cyclic nucleotide 3’-phosphodiesterase; NO: nitric oxide; GFAP: 
glial fibrillary acidic protein; NCAM: neural cell adhesion molecule; CNTF: ciliary neurotrophic factor; BDNF: brain-
derived neurotrophic factor; NGF: nerve growth factor; NSE: neuron-specific enolase; Nf: neurofilaments; NAA: N-
acetyl aspartic acid. 
 
Table 2.3 shows a few of the proposed molecular biomarkers with the associated disease 
phenotypes or specific processes e.g. inflammation or demyelination. This could be helpful to 
segregate and creating a unique profile of each patient based on the processes. In addition, 
monitoring certain processes (e.g. remyelination) after the administration of a drug would help 
health care professionals to formulate appropriate medication regimens. An up-to-date and 
comprehensive list of molecular biomarkers is discussed later (Table 2.5).  
Besides molecular biomarkers, there are also anatomical biomarkers as well as techniques which 
allow us to quantify the phenotypes and identify the disease severity. These include number and 
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volume of different lesions in different regions of the brain. Table 2.4 provides a list of 
techniques and potential imaging biomarkers associated with them.  
 
 
 
Technique Markers 
T1 Number and volume of T1 lesions; presence of black holes 
T2  Number and volume of T2 lesions 
Gd Number and volume of Gd-enhancing lesions 
Brain volume 
Brain parenchymal fraction; grey matter volume; white matter volume; cervical spinal 
cord volume; regional volumes 
Magnetization transfer Magnetization transfer ratio 
MR spectroscopy NAA, glutamate, glutamine, GABA, choline, creatinine, myoinositol, ascorbic acid 
Diffusion MRI Mean diffusivity; diffusion tensor 
Functional MRI Regional activation 
Fractal dimension White matter FD; gray matter FD 
Optical coherence 
tomography  Thickness of the RNFL; macular volume 
Table 2.4: Different techniques and imaging biomarkers for MS prognosis, edited version of [105]. MRI: Magnetic 
resonance imaging; Gd: gadolinium; NAA: N-acetyl aspartic acid; GABA: Gama Aminobutyric acid; RNFL: retinal 
nerve fiber layer. 
 
Villoslada et al., [106] recently published a comprehensive list of MS associated molecular 
biomarkers with their types and status (possible, known or exploratory). The types of biomarkers 
include HLA, Activation markers, Adhesion molecules, Antibodies, Antigens, Cell phenotypes, 
Chemokines, Complement, Cytokines, Genes, Lipids, Metabolites, mRNA, Oligoclonal bands, 
Proteins and Viruses. The categorization is not strict but the table provides a summary of 
molecules for possible candidates for better diagnostics, drug discovery, and treatment of the 
disease.  
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Type Examples Status1 
DNA 
HLA HLA-DRB1 (1501, 1503, 0801, 0301, 0401, 1401), DRB5, HLA-DQA, HLA-DQB (0603), 
HLA-C 
Possible 
Gene2 IL7R, IL2RA, CLEC16A, CD68, CD226, RPL5, DBC1, ALK, FAM69A, TYK2, CD6, 
IRF8, TNFRSF1A, SCIN, IL12A,  MPHOSPH9, RGS1, KIF21B, TMEM39A 
Possible 
Genes3 ADAMTS14, AGER, ALS2, ALOX5, BANK, CD226, CCDC97, CYP2S1, CTLA4, 
FAM5A, LECAM2, GCCR, GSK3B, GPC5, AFGF, E1BAP5, ITGA4, ICAM1, IRF1, 
IFNGR1, IFNGR2, IL10, IL12, IL13, IL2RA, IL23R, IL3, IL4, IL4R, IL5, IL6, IL7, IL7R, 
IL9, CMT2A, GLOD1, PTPRC, FDC, LFA3, MMP7, MMP9, TIMP3, MICB, MAPT, 
SLC25A8, MBP, MAG, MPO, CMT1F, NPAS3, NPTXR, NT3, CARD15, OPN, CMT1A, 
PAI1, PECAM1, PLA2G7, PRR2, POU2AF1, GGF2, NKNA, JAG1, PKCA, HIP, PON1, 
STAT1, FLJ22950, LAP18, MMP3, SOD1, SYN3, PLAT, TCF7, TGFB1, TGFB2, TNFA, 
NGFR, GITR, TNFR2, TNFRSF5, 4-1BB, AXL, VEGF, VAMP 
Exploratory 
Genes4 CASP3, TRAIL, FLIP, COL25, GPC5, HAPLN1, CAST, STAT1, IFNAR1, IFNAR2, 
MX1, IFNG, IL10, GRIA3, CIT, ADAR, ZFAT, STARD13, ZFHX4, FADS1, MARCKS, 
IRF2, IRF4, IL4R, CASP10, CASP7, IL8, IFIT3, RASGEF1B, IFIT1, OASL, IFI44, 
IFIT2, HLA-DRB1*1501, TCRB, CTSS 
Exploratory 
mRNA PDGFRA, BAX, BCL2, APAF1, API1, CASP1, CASP2, CASP6, CASP8, CASP10, P53, 
COL3A1, DOCK10, ADAM17,  EGR2, EPHX2, EAAT1, G3PD, C11, HBB, HAVCR, 
IFI6, IFITM1, IFITM3, IFNAR1, IFNAR2, ISG15, MX1, G10P1, G10P2, IL1B, IL1A, 
IL10, IL12, IL4, IL5, CLEC5B, LY6E, LT, LAPTM5, MIF, MBP, MYD88, SIR2L1, 
NOTCH2, FLJ00340, EBP-1, RIP15, PRDX5, PLSCR1, PSEN2, PDCD2, PDCD4, 
PARK7, JAG1, PKB, RSAD2, EB9, HIP, NOGO, STK17A, TLR4, TLR6, NFKB3, 
TGFB1, TRIB1, TNFA, TRAIL, TNFSF12, APRIL, FASL, TNFRSF12A, UBE4B, 
XIAPAF1, RASGEF1B, OASL, MARKS 
Exploratory 
Proteins 
Oligoclonal bands IgG index, IgG OCB, IgM OCB, light chains Known 
Antibodies Anti-MBP, anti-MOG, anti-GalC, anti-PLP, anti-OSP, anti-CNPase, anti-transaldolase, 
anti-proteasome, anti-β-arrestin, anti-Gangliosides, anti-CRYAB, anti-HSP60, anti-HSP70, 
anti-HSP90, anti-ATP2C1, anti-KIAA1279, anti-PACSIN2, anti-SPAG16, anti-hnRNP B1, 
anti-Alu repeats, anti-NG2, anti-phosphatidylcholine, anti-NF, anti-NogoA, anti-tubulin, 
anti-enolase, anti-glycan, anti-triosephosphate isomerase (TPI), anti-GAPDH 
Exploratory 
 
Anti-AQP45 Known 
 
Neutralizing antibodies of interferon β or Natalizumab Possible 
Cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-15, IL-17A, IL-18, IL-23, TNF-
α, TGF-β, interferon β, interferon γ 
Exploratory 
Chemokines CCR2, CCR5, CCR7, CCL1, CCL2, CCL3, CCL4, CCL5, CCL8, CCL17, CCL21, 
CCL22, CXCR3, CXCR4, CXCL5, CXCL10, CXCL12, CXCL13 
Exploratory 
Complement C3, C3d, C4, C7 neoC9 Exploratory 
Adhesion molecules ICAM-1, VCAM-I, E-selectin, L-selectin, LFA-1, VLA-4 Exploratory 
Activation markers CD25, CD40, CD80, CD86, CD26, CD30, OX40, Fas, TRAIL, OPN, CD127, CD45, 
CD47, CD16, CD279, CD163, T-bet, CD1d, CD266, GITR, TNFR2 
Exploratory 
Other αβ-Crystallin, neurofilaments (light-chain), tau, actin, tubulin, 14-3-3, neuronal enolase  Possible 
  Nogo-A, Lingo, ALDH, α1B glycoprotein, α2-HS-glycoprotein, α-synuclein, Aβ, ANX1-5, 
ApoA (I, IV, B, D), API1, βADRBK1, Arrestin, beta 1, beta-End, NGF, BDNF, CNTF, 
BRCA1, CRP, CB2, CD276, CD44, chitotriosidase-1, chromogranin A, clusterin, 
contactin1, cystatin C, CD26, Mac-2 BP, gelsolin, GFAP, haptoglobin, iNOS, IGFBP-3, 
interferon α, interferon γ, MxA, IL-1ra, kallikrein-1, kallikrein-6, Manan-binding lectin 
serine protease-1, MMP-9, TIMP-3, MICB, MBP, MAG, NT3, OLIG2, P2X7R, PDGFB, 
PD-L1, PD-L2, IGFBP3R, COX-2, DJ-1, PACSIN2, protein C inhibitor, S100A, S100B, 
RBP4, secretogranin I, transferrin, serum paraoxonase/arylesterase 1, Stat-1, SCN2A, Sox-
9, Sox-10, SPAG16, MMP-3, SOD1, tetranectin, tPA, transferrin receptor, TGF-β, 
peripheral benzodiazepine receptor, transthyretin, TNFSF12, tissue factor, Fas, vitamin D-
binding protein, VDAC1, AZGP1  
Exploratory 
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Type Examples Status1 
Metabolites  Folic acid, homocysteine, prostaglandin E2, vitamin D, vitamin B12 , vitamin B6, 
hydroxyindoleacetic acid, iron, malonaldehyde, N-acetylaspartate, neopterin, nitrates, 
orosomucoid, sorbitol, thiobarbituric acid reactive species, cholesterol, 24S-
hydroxycholesterol 
Exploratory 
Lipids  Galactocerebroside, gangliosides, sphingolipids, phosphatidyl-serine, oxidized cholesterol 
derivatives  
Exploratory 
Antigens  MOG, MBP, PLP, β-arrestin, contactin 2,  Exploratory 
  AQP4 Known 
Cell phenotypes  Treg (Foxp3+, Tr1, CD8reg)  Possible 
  Breg, NK cells, CD4, CD8, B cells (CD5+), macrophages, DC (myeloid and plasmacytoid)  Exploratory 
Viruses  EBV, HHV-6, MSRV, VZV  Exploratory 
 
1Status shows different types of biomarkers taken from IntegrityTM  
2Genes found and validated in GWAS 
3Genes marked as biomarker in IntegrityTM 
4Genes identified in pharmacogenomics studies in Interferon-beta therapy 
 
Table 2.5: A comprehensive list of MS biomarkers, their type and status, edited version of [106]. 
 
2.6 Therapies of multiple sclerosis: 
Few therapeutic options are currently available to MS patients, and none cure or eliminate the 
disease completely. The available pharmacology regimens either only suppress the progression 
of the disease by reducing the symptoms, or bring about the recovery phase in certain disease 
subtypes. Further, PPMS does not have any approved drug thus far [107]. Most of the drugs have 
an influence on immunosuppression, thus preventing an immune system attack. Different types 
of drugs are prescribed based on the clinical manifestations of the disease. Corticosteroids are 
given to reduce attacks, e.g. prednisone or intravenous methylprednisolone, which reduce nerve 
inflammation. Beta interferon and Glatiramer acetate have been shown to reduce the frequency 
of relapses and stop autoimmune attacks on the myelin sheath, respectively. Both of the drugs 
are used as first line therapy and are the first choice of treatment by clinicians after diagnosing 
the disease. Another first line drug is Fingolimod, which has been recently approved and became 
the first oral drug for MS. Fingolimod inhibits lymphocyte emigration from lymphoid organs. 
Natalizumab, a strong antibody which targets VLA-4, is often prescribed as a second line 
therapeutic agent. It has a very high efficacy, but is also associated with side effects, such as 
progressive multifocal leukoencephalopathy.  
The sequential line of therapies suggests that the drugs being prescribed as first line therapy are 
targeting the molecules and pathways involved in the early stage of MS. This provides intrinsic 
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knowledge about the order of disease progression, e.g. molecules affected by first line therapy 
would activate earlier than molecules affected by second line therapy. Following the path of 
modeling molecules involved in different lines of therapies would unravel a chronological model 
of MS. Table 2.6 shows a list of drugs segregated by their respective lines of therapies (1st line or 
2nd line) and their mechanism of action. By looking at the mechanism of action, one could argue 
that the progression of the disease follows the same pattern. 
 
Group  Therapy Proposed mechanism of action Comments 
First line  Interferon-ß Complex (i.e., inhibition of BBB 
transmigration and  Th17-cells, promotion 
of regulatory lineages) 
Moderate efficacy, Good side 
effect profile, Neutralizing 
antibodies 
  Glatiramer 
acetate 
Complex (promotion of regulatory 
lineages) 
Moderate efficacy, Good side 
effect profile 
  Dimethyl 
fumarate 
Not clear, Immunomodulation Moderate efficacy, Oral agent 
  Teriflunomide Pyrimidine synthesis inhibitor, Impairs T-
cell activation 
Moderate efficacy, Risk of 
hepatotoxicity, Oral agent 
  Fingolimod S1P-receptor modulator, Inhibits 
lymphocyte emigration from lymphoid 
organs 
High efficacy, Risk of infections 
and cardiac side effects, Oral agent 
Second line  Natalizumab Anti-CD49d antibody, Inhibits BBB 
transmigration 
High efficacy, Risk of progressive 
multifocal leukoencephalopathy 
  Mitoxantrone Immunosuppressive agent, Induces 
lymphopenia 
High efficacy, Risk of 
cardiomyopathy and secondary 
leukemia 
  Azathioprine Immunosuppressive agent, Induces 
lymphopenia 
Moderate efficacy, Risk of 
malignancies, Oral agent 
Promising 
agents 
Rituximab 
/Ocrelizumab 
Anti-CD20 antibody, Depletes B-cells High efficacy, Side effect profile 
unclear 
  Daclizumab Anti-CD25 antibody, Induces regulatory 
NK-cells 
High efficacy, Side effect profile 
unclear 
  Alemtuzumab Anti-CD52 antibody, Depletes 
lymphocytes 
High efficacy, High risk of B-cell 
mediated autoimmunity 
  Laquinimod Not clear, Immunomodulation Oral agent 
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Table 2.6: Different lines of therapies and their proposed mechanisms of action, edited version of [35]. 
A recent review demonstrates that different approaches are being taken to treat MS by targeting 
multiple sets of molecules based on the vicinity of the drugs’ actions [108]. Figure 2.8 shows 
various drugs acting on different compartments.  Rituximab, Alemtuzumab, Daclizumab and 
Natalizumab are monoclonal antibodies (denoted by the suffix –mab) which interact with 
different CD molecules, NK cells, and VLA-4 in the periphery of blood-brain barrier. Cladribine 
and Teriflunomide are therapies which prevent new T-cell formation. Fingolimod (FTY720) 
interacts with sphingosine-1-phosphate receptor (S1P-R) in the CNS or in BBB periphery 
(Figure 2.8). Fingolimod is also able to permeate through the BBB. In the CNS, Laquinimod and 
Fumaric Acid play a role in the reduction of disease severity via the interaction with T-helper 
cells. Laquinimond inhibits TH17 while Fumaric Acid interacts with TH2 cells.  
 
Figure 2.8: Drug actions on the different molecules associated with MS, taken from [108]. The blue square boxes show the 
name of drugs. The round shapes represent the different types of immune cells. The green boxes represent the sites where 
these interactions are taken place. 
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Despite the knowledge and variety of drug treatments available, the struggle to stop and reverse 
neural degeneration in MS continues. Although the drugs discussed above provide relief of 
symptoms, it is only short term relief, and a complete cure is still beyond reach. In addition to the 
lack of cure, no treatment exists which slows an aggressive form of the disease such as PPMS. 
One reason a cure has not yet been found may be that researchers currently focus primarily on 
various single aspects of the disease. MS is multi-factorial and systematic; one might infer that a 
cure can be found through a multi-factorial and systemic approach. Systematic approaches can 
help find a cure for diverse polygenic diseases, as demonstrated in the case of breast cancer, in 
which an experimental systemic therapy was found to reduce metastatic extravasation [109]. 
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3 Chapter 3: Systems Biological approaches to model MS 
3.1 Introduction to Systems Biology: 
Systems biology is an emerging field which enables scientists, particularly biologists, to look at 
the whole picture of a specific biological phenomenon. One of the rationales behind systems 
biology is the notion that, “The whole is greater than the sum of its parts”. There are many 
definitions of systems biology [110]; one of the earliest and simplest definitions is from Kitano: 
“A systems biology approach requires the integration of experimental and computational 
research to understand complex biological systems” [111]. Systems biology is crucial, since 
complex diseases are polygenic and therefore require a better understanding of the non-linear 
interactions among the molecules involved in their pathogenesis. Drugs against complex diseases 
can only be effective if networks, rather than individual molecules, are targeted. Systems biology 
is also known as integrative biology, as depicted in figure 3.1. Different approaches have been 
integrated to solve biology problems, e.g. information sciences, system sciences and biological 
sciences. The integrative approach allows researchers to connect multiple layers of datasets in a 
multi-dimensional paradigm for complex mechanism modeling. 
Systems biology aims to investigate biological systems by capturing and integrating global 
biological datasets from different hierarchical organizations, in order to visualize emergent 
properties. The term emergent properties, also known as collective properties, is used to describe 
the intrinsic properties of a system which cannot be predicted by studying individual components 
of the system [112]. Systems biology uses a holistic approach, utilizing all technological 
advancements to obtain the minute details and features of each component of a system. 
Computational tools, such as data mining, help to reveal the knowledge buried under piles of 
data. System sciences help to build models, at different resolutions by using multi-level datasets, 
which describe various complex biological phenomena and provide analytical insights. The 
availability and interoperability of publicly accessible datasets of different types and levels such 
as genome sequences, Protein-Protein interactions, high throughput and functionally annotated 
databases made it easier to interconnect different molecules with their contextual information in-
silico, thus facilitating simulation and prediction. In summary, systems biology makes use of 
approaches taken from different domains, as well as addresses challenging tasks such as drug 
discovery, polypharmacology, pharmacovigilance, and personalized medicine [113]. 
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The following four areas are considered to play a key role in systems biology [114]: 
(1) Genomics and other molecular biology research 
(2) Computational and bioinformatics tools, e.g. modeling and simulation software 
(3) Analysis and dynamics of the system  
(4) Technological advancement for high precision measurements 
 
 
Figure 3.1: A descriptive diagram of Systems Biology, edited version of [114]. 
 
As discussed above, the ultimate applications of systems biology are to foster drug discovery and 
to unravel the molecular mechanisms behind complex processes. Even though the application of 
modern molecular biology techniques significantly advanced the way drugs are being designed, 
the struggle to find a cure for many diseases continues. For example, the discovery of new 
isolation techniques allowed researchers to identify the molecules responsible for disease 
conditions, observe molecular behavior after treatment with certain compounds, and discover 
molecular interactions. More recently, the post-genomic era brought a large amount of new data 
such as genes, gene products [115],  and protein connectivity maps [116–118]. Remarkable 
progress has been made in the ability to acquire this data. In order to cure complex diseases, the 
interpretation of such a large amount of data requires a systematic approach. Biological systems 
should be considered in their entirety.  
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In the recent past, it was discovered that most of the common diseases such as cancer, 
neurodegeneration and cardiovascular diseases are the outcome of many different molecules’ 
dysfunction [119,120]. Additionally, researchers discovered that the human genome has many 
more levels of organization and regulation than previously anticipated; thus a systematic level 
study of organization and interpretation is essential. This drives researchers to look not only at 
any individual molecule, but rather to study them in relation to their often complex interactions. 
One common approach in systems biology is to develop a molecular interaction map, analyze the 
pathways, model molecular systems to find out the key molecules involved in the disease state, 
and then use this knowledge for therapeutic intervention [121]. Systems biology allows 
researchers to look at the complexity of biology as a whole and model knowledge with different 
layers of complexity, as well as to make predictions based on the state of the system. With this 
kind of systematic approach, a study [122] demonstrated that in response to a drug, 
approximately 1000 different molecules of a H1299 lung carcinoma cell behaved differently than 
they did before treatment. This shows that the perturbation caused by drugs is not limited to a 
few molecules, but rather affects large networks. This demonstrates that a better understanding 
of drugs’ actions is only possible through analyzing the whole system. Table 3.1 shows the 
comparison of Traditional drug discovery approach vs. Systems biology approach. 
 
Traditional drug discovery approach Systems biology approach 
Reductionist approach Holistic approach 
Inhibition of single drug target 
Inhibition of one or more key targets at converging 
point in disease pathway 
Non-account for organism's compensatory mechanism Account for organism's compensatory mechanism 
High risk in animal model to clinical translation          
Animal model to clinical translation guided by 
biomarker(s) 
High risk in clinical study relying solely on efficacy 
endpoints 
Mitigated risk in clinical study as biomarker 
reduction used as early decision endpoint 
Nonconforming to personalized medicine Facilitating personalized medicine 
Table 3.1: Comparison of Traditional drug discovery approach vs. Systems biology approach. Edited version of [123]. 
 
In addition to the discovery of new drugs, the improved understanding of entire complex systems 
could be used to prevent diseases and improve healthcare by allowing scientists to focus on the 
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key molecules involved. Another example of this systematic approach is an experimental therapy 
against breast cancer, in which EREG, COX2, MMP1, and MMP2 were found to be key genes. 
Inhibitory action against them resulted in a spectacular reduction of metastatic extravasation 
[109]. With this evidence that one often needs an alternative such as systems biology in order to 
understand and affect complex diseases, one might expect that systems biology itself offers a 
range of options to suit various investigative or treatment purposes. Two well-known systems 
biology approaches, bottom-up and top-down, will be discussed in the following sections. 
3.2 Bottom-up systems biology: 
The bottom-up systems biology approach starts with fine granularity. The interactions of 
molecules are studied in order to unravel their functional attributes. Individual components of the 
systems are modeled to provide the mechanistic details, dynamics, and simulations closer to 
actual biological processes. The bottom-up approach can be started by a simple literature search 
about a molecular entity and exploring interactions. Enrichment of the interactions with specific 
experimental studies depends on the interests of the researcher and on data availability. For this 
approach, prior knowledge of most of the molecular interactions is required.  
Different kinetic models, which represent and simulate signaling processes, e.g. the virtual heart 
model [124] and the silicon cell model [125,126], have been developed by using this approach. 
Besides models, many databases have been assembled by using the same approach e.g. KEGG 
[127] and EcoCyc [128] etc. 
3.3 Top-down systems biology: 
The top-down systems biology approach attempts to build in-silico models by processing high-
throughput experimental studies. This approach helps to model the system on a high-level 
resolution, considering only the input and output behaviors of a model. The top-down approach 
is ideal for experimental methods that are data rich; it facilitates valuable insights from large 
datasets by modeling and inferences [129,130]. One of the advantages of this approach is that, 
often, prior knowledge is not needed to generate hypothesis; thus many different pathways can 
be analyzed simultaneously. Contrary to the bottom-up approach, the top-down approach is 
based on data and can be considered a data-driven approach. Large datasets are required of gene 
expression, proteomics, affinity assays, etc. to work with this approach. The starting point of this 
model building approach is to have a comprehensive dataset, often generated by –omics 
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technologies (genomics, proteomics, metabolomics etc.). The dataset is then used to infer the 
mechanisms underneath, such as phenotypes or disease subtypes, by identifying specific 
pathways or modules and their components. One of the strategies for using this approach is the 
integration of various datasets to provide a dynamic state of the model. The top-down approach 
can be applied to different phases of system modeling e.g. the module discovery phase, the 
knowledge-based static modeling phase, or in various later phases. Bayesian modeling may be 
used to unravel the regulatory components. The top-down approach can also be used for time 
series models, e.g. disease progression or changes in physiological states. In addition, the 
approach can also be used to observe perturbed systems [131], e.g. to monitor a drug therapy and 
any global changes it might cause. Gene-set enrichment analysis, pathway mapping, disease 
classification, reverse causal reasoning, and network inference are few methods categorized 
under this approach [132]. Clustering techniques have also been used to infer novel relationships 
among groups of genes by using the same approach [133–135].  
A few drawbacks of using the top-down approach are: limited opportunities to discover a unique 
and specific mechanism without intertwined interactions, findings which are often based on 
correlation rather than cause and effect, and difficulties in finding relevant supportive knowledge 
of a network once a correlation between genotype and phenotype has been revealed.  While the 
bottom-up approach does not produce results with these complications, it is nevertheless limited 
in that most results are obtained using transgenic animals rather than humans. Thus, the accuracy 
of this knowledge in the context of human disease is questionable [136]. Figure 3.2 shows the 
different perspectives of the top-down and the bottom-up Systems biology approaches.  
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Figure 3.2: Difference between the two Systems biology approaches. Top-down approach starts from System and then 
goes to single component, while Bottom-up approach starts from single component and then goes to System. 
 
Bottom-up approach has been used to model many molecular interaction maps of diseases with 
the initial seed entities, and then to expand the network with other relevant knowledge. These 
networks have been developed to discover potential drug candidates for diseases such as 
rheumatoid arthritis [137], Alzheimer’s disease [138] and hepatitis B [117]. In addition to the 
bottom-up approach, the top-down approach has also been widely used on high throughput 
datasets; for example, to elucidate the mechanism behind neurotoxicity in Alzheimer disease 
[140]. Since both approaches have their drawbacks, an integrated approach would be the answer 
to the challenges and may accelerate the discovery of new drug targets due to the unique 
strengths of each of the approaches. In the following section various computational techniques 
and approaches have been discussed to model the disease. 
3.4 Text mining and systems biology: 
Text mining is a computational technique used to discover new and unknown information by 
processing written resources [141]. There are many processing steps, including information 
retrieval, information extraction, and natural language processing. Text mining is one of the 
crucial techniques in systems biology toolkit. It facilitates the rapid processing of millions of 
documents, as well as the extraction of important information from them. With this capability, 
text mining could provide a solution to help the scientific research community cope with the 
rapidly increasing numbers of scientific publications. An estimated 500,000 new citations are 
added each year to PubMed, which already contains approximately 24 million citations [142]. 
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Text mining has been used extensively to identify disease-related molecules, such as genes and 
proteins, and to understand their functions. Many databases use text mining tools to process 
entire contents of PubMed and extract information from the available scientific text for novel 
discoveries. In addition to the increasing number of publications, the availability of databases is 
also growing in number and variety; for example, microarray, genome-wide association study 
(GWAS), and pathway databases. The table 3.2 below shows a list of some of the databases and 
tools: 
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Text/Structural databases 
PubMed Central http://www.pubmedcentral.nih.gov 
HighWire Press http://highwire.stanford.edu 
E-Biosci http://www.e-biosci.org 
PubMed http://www.ncbi.nlm.nih.gov/pubmed 
UniProt http://www.uniprot.org 
InterPro http://www.ebi.ac.uk/interpro/ 
Text Mining Tools 
Google Scholar http://scholar.google.com 
GoPubMed http://www.gopubmed.org 
Textpresso http://www.textpresso.org 
BioRAT http://bioinf.cs.ud.ac.uk/biorat 
ABNER http://pages.cs.wisc.edu/~bsettles/abner 
iHOP http://www.ihop-net.org/UniPub/iHOP 
GeneWays http://geneways.genomecenter.columbia.edu 
Microarray databases 
SMD http://genome-www5.stanford.edu 
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo 
Oncomine http://www.oncomine.org 
CGAP database http://cgap.nci.nih.gov 
caArray http://array.nci.nih.gov/caarray 
Gene Expression Atlas http://symatlas.gnf.org 
Clustering Platform 
GenePattern http://www.broad.mit.edu/cancer/software/genepattern 
GeneCluster 2 http://www.broad.mit.edu/cancer/software/genecluster2/gc2.html 
ArrayMiner http://www.optimaldesign.com/ArrayMiner/ArrayMiner.htm 
Supervised Analysis Platform 
SAM http://www.stats.stanford.edu/~tibs/SAM 
Pathway and interactome databases 
KEGG http://www.genome.jp/kegg 
UniHI http://theoderich.fb3.mdc-berlin.de:8080/unihi/home 
PathwayExplorer http://pathwayexplorer.genome.tugraz.at 
GenMAPP http://www.genmapp.org 
Pathguide http://www.pathguide.org 
Table 3.2: Some of the popular websites for text mining, microarrays, pathway databases, and associated tools, taken 
from [143]. 
 
3.5 Systemic modeling approaches and their advantages: 
Models are essential to the understanding, prediction, and control of the system; in biology, all 
three are needed for drug discovery. Models have been always important in life science research, 
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whether they are living organism models or computational models. Modeling biological systems 
is a major application of systems biology. The development of models which represent and 
describe a biological system is crucial for simulating a physiological state in-silico. Systems 
biology provides a framework to integrate multi-dimensional data, thus facilitating the 
generation of models with complex attributes. Integration capabilities of the framework are 
required in order to have a holistic approach, which facilitates the understanding of the structures 
and dynamics of intercellular and intracellular interactions, as well as understanding cell 
functionality. Different granular layers of interactions can be modeled to understand the 
functionality of different modular components, with respect to their compartments. 
Modeling and simulation made it possible to predict the output of a variety of scenarios without 
even conducting an experiment. Figuring out the interactions between macromolecules, cells, 
tissues, and their respective dynamics is always a challenging task for researchers. Mathematical 
formalization has been used to study biological systems [144–146]. In addition, system level 
modeling helps to modularize different components and dissect large components into individual 
elements, in regards to their underlying dynamic interactions. Mathematical modeling has been 
used widely at different abstract levels and it records the behavior of individual molecules with 
kinetic details. Many modeling methods e.g. ordinary differential equation, stochastic modeling, 
flux balance analysis, and metabolic control analysis have been used to model biological systems 
[147]. 
Ordinary differential equation (ODE) models usually require a large number of kinetic 
parameters; generally, the kinetic data is either limited or unknown. This makes ODE models a 
poor choice for our work, as kinetic data was not available for most of the interactions. 
Stochasticity plays an important role in biological networks [148], as it includes randomness in 
certain events which occur spontaneously in biological systems, e.g. switching from non-lytic to 
lytic mode of different phages and diffusion of molecules across a membrane. We used 
stochasticity partially in our agent-based modeling work (discussed in later chapters). Flux 
balance analysis (FBA) is mostly used to quantify the metabolic state of a cell by means of 
constructing metabolic networks and modeling metabolic pathways. Metabolic control analysis 
(MCA) is a method for analyzing key reactions of metabolism and has also been used to identify 
cell cycle reactions. One of the drawbacks of the approach is that MCA can only be performed if 
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models are defined in terms of reaction stages. On the other hand, the higher level of abstraction 
in equations provides a generalization of the system phenomena.  
The aforementioned modeling methods could help us to accomplish the following objectives: 
● Optimizing strategies for certain drug treatments 
● Identifying viable drug targets 
● Understanding drug effects, pharmacodynamics, and pharmacokinetic properties 
● Repurposing eligible drugs 
In the following chapters, these aspects of modeling will be discussed briefly. 
3.6 Systemic modeling and drug discovery: 
Computational disease modeling (CDM) is an important method of systems biology by which 
pharmaceutical companies could avoid dried-up drug pipelines, cope with unmet medical needs, 
and further treatment options for patients. CDM is defined as the mathematical and computable 
modeling of a disease which can simulate the disease’s state, progression, and dynamics. CDM 
has the potential to significantly reduce the timeline of drug development and the cost involved 
therein. Either of these hinders the progress of drug development. Developing a drug often takes 
12-15 years and can cost up to $1.7 billion [149]. CDM could help in designing strategies to hit 
multiple targets and relevant pathways of a disease, while also predicting possible side effects of 
drugs [150–152]. A recent study demonstrated that CDM helped to optimize therapeutic 
strategies by identifying multi-factorial components of the system [117].It could also allow 
researchers to predict the outcome of combinatorial therapy, the best dosage possible, and the 
most favorable target. With computational disease models, one could simulate the disease 
condition and observe it in regards to the whole system. A success story of computer based 
modeling surfaced when the U.S Food and Drug Administration (FDA) approved the first ever 
computational model as a substitute for pre-clinical animal testing for new treatment of diabetes 
mellitus type 1 [154]. 
3.7 Qualitative modeling: 
Qualitative modeling is a type of modeling which deals with the continuous aspects of a system. 
Sometimes it is also called qualitative reasoning [155]. This modeling technique is used when 
numeric details of system components are not known; instead, increments, decrements, highs, 
and lows are being used. The goal of this technique is to represent and reason the system 
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computationally without quantitative values. This technique provides a possibility to model 
systems which are too complex to model otherwise, due to the different constraints and the 
descriptive nature of the system. Qualitative models aim to infer as much as possible from 
minimal observations and descriptions of the system, rather than from mathematical equations. 
Qualitative models provide an abstract view of the system, as minute details are often 
overlooked; they specify objectives and their basic parameters, qualitative interrelationships, and 
underlying hypotheses. They transform an objective statement and a hypothesis into a conceptual 
model, which can be enriched with equations. These can then be transformed into quantitative 
models by the addition of mathematical equations, as shown in the case of Petri-net models 
[156]. Qualitative models can be presented in different forms but mostly are represented by 
diagrams. Diagrammatic models represent system entities as nodes and relations as edges, such 
as the models available in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
[127].  
3.8 Quantitative modeling: 
Quantitative models require an extensive knowledge of their components and mathematical 
equations. Quantitative modeling is based on mathematical and statistical methods. This 
modeling approach is used to interpret numerical data and to develop mathematical models based 
on which simulations and hypotheses or predictions can be generated. It also makes use of 
measurements and the manipulation of variables to see the global effect of numerical value 
change.  
The quantitative aspect of modeling often comes later than the qualitative aspect. This happens 
because modeling requires a system, which specifies the objects, their basic descriptors, the 
qualitative interrelationship, and any underlying hypotheses before it can enrich them with 
numerical values and equations. Quantitative models are very efficient for modeling system 
dynamics and providing accurate predictions, if sufficient data is available, which is 
unfortunately not the case with neurological disorders. However, there is large amount of textual 
data available and one can mine those to build some text based knowledge models. Molecular 
interactions maps are one of the many approaches to model disease after information retrieval. 
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3.9 Molecular interaction maps: 
Molecular interaction maps (MIMs) are interaction maps of molecules that are involved in a 
biological function. These interaction maps may also be called interactomes [157], molecular 
interaction networks [157], protein-protein interactions [158], protein-DNA networks or gene 
regulatory networks [159], depending on their scope and components. They are based on graphic 
representations or diagrams of physical interactions among different molecules in an organism, 
either in a compartment or in a physiological state. As pointed out by Ideker et al. [160], graphic 
representation or diagrams can be “a tremendous aid in thinking clearly about a model, in 
predicting possible experimental outcomes, and in conveying the model to others”. MIMs make 
it convenient to visualize all possible interactions of a molecule. Most proteins interact with 
many other molecules to form complexes and networks. Each human protein interacts with 
roughly 15 other molecules [161]. MIMs are developed from different sources; it could be 
experimental data, biochemical data, or published literature. MIMs are used to discover overall 
functionality and the regulatory processes of a biological system, as well as the pathophysiology 
of complex human diseases [162].In addition, they can be used to identify novel biomarkers, 
pathway crosstalk and molecular characterization of complex diseases [143]. In MIMs, each 
node represents a molecule (gene or protein) and each edge represents an interaction. Most 
MIMs are undirected, which means they do not show the flow of signaling between two 
molecules.  
Exploring the disease mechanism has been considered an important application of MIMs, and 
many MIMs are developed [137,139,162–166] to reveal the mechanistic details of molecular 
machinery behind a disease state. Traditional disease maps do not distinguish cause and effect, as 
they lack the directionality of the events. These maps leave the impression that interacting nodes 
are somehow related, without explaining whether they are participants in a reaction or product. 
One approach to develop MIMs is based on information retrieval. It could be started by a simple 
search of PubMed and then ranking the molecules based on their association with the disease. 
Due to the increasing numbers of MIMs, a community-based portal Payao [31] has been 
launched to help scientific community with interactive knowledge sharing in systems biology 
languages. 
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3.10 Systems biology languages: 
There are many languages which can represent biological data and facilitate the exchange of 
information from one platform to another. Many factors are involved in choosing the appropriate 
language for answering specific questions, based on the aim of the work. Factors include, but are 
not limited to, a variety of tools available to support the language, very expressive (in terms of 
biological reactions) or enrichment capabilities, and the preservation of knowledge when 
transformed into other formats. We were interested to model and simulate biological data with 
the possibility to use modeling knowledge in other platforms such as Mediawiki, thus systems 
biology markup language (SBML) was chosen. A plug-in has been developed which transforms 
SBML into wiki pages, thus allowing knowledge sharing beyond specific tools (discussed in 
later chapters). There are hundreds of tools available which extend the possibilities of SBML 
functionality; thus, SBML was the best choice for the current work on disease modeling. A brief 
description of various biological modeling languages, featuring their respective strengths and 
limitations, is given below.  
3.10.1 Systems biology markup language (SBML): 
Computational modeling in biology is no different from traditional computational modeling, 
except that models are developed from biological data. Like any other model the biological 
models are computable, can be simulated, and can be analyzed by mathematical methods. Many 
different representations of models are used for different purposes. Systems biology graphic 
notation (SBGN) is a graphical representation for biological processes [167]. To make models 
computable with enriched and dynamic biological systems, a quantifying format is required; 
(SBML) [168] satisfies this requirement.  
SBML is a machine-readable format for model representation. This representation emphasizes 
the chronological order of biochemical events, such as molecular entities’ transformation into 
complexes, and entities’ reactions as involved in a biochemical network. SBML framework is 
suitable for representing models, including cell signaling pathways, metabolic pathways, 
biochemical reactions, and gene regulations. 
SBML is based on Extensible Markup Language (XML) and is a representative format for 
computable biological models. It is free with open interchange format and extensive software 
support; to date, there are 280 software systems which provide support for SBML [169]. Many 
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biological phenomena can be represented by SBML, such as metabolic networks, cell signaling 
pathways, regulatory networks, and infectious diseases. Since its inception, SBML has become 
the standard for systems biology models representation. It has enabled the exchange of models 
between different software tools, thereby streamlining and enhancing framework 
interoperability. 
 
 
Figure 3.3: Example of encoded SBML Model. The knowledge is embedded with different Tags and in a 
structured format.  
 
As it represents participant dependent, reaction-type processes, SBML is not specific to 
biochemical network modeling. The same formalism could also be used in other types of 
processes and in expressing different functions of the system. SBML also supports direct 
mathematical expression and formulas, extending its capability to merely represent biochemical 
reactions [170]. SBML has following two main purposes: 
● Enabling the use of different software tools without reconstructing the models for each 
application-specific file format, thereby creating the ability to share the models among 
people using different applications. 
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● Extending the longevity of the models beyond the lifetime of the software used to 
develop them. 
SBML’s purpose is to serve as an exchange format used by different contemporary software 
tools, in order to communicate essential aspects of a model.  
3.10.1.1 Main features of SBML: 
SBML can develop models based on entities and reactions. An excellent feature of SBML 
models is that they can be deconstructed into constituent elements easily, thus making them 
interchangeable into various formats and then readable by different forms of tools being used. 
Different software programs can read and transform SBML models into the required format for 
further processing. SBML allows model representation with rather arbitrary complexity. All 
constituents of the models are defined by using a specific type of data structure, and knowledge 
is embedded within various layers. The data structures determine the encoding layout in XML. 
Furthermore, each entity can have machine-readable metadata associated with it. These 
annotations can be used to encode reaction details among the entities in a model as well as to 
encode the external identifiers of the entities, e.g. UMLS CUIs and Drugbank ID. The 
BioModels database utilizes this feature by annotating each model and providing references of 
the associated resources, i.e. research articles, databases, pathways, etc. Annotations make a 
model more meaningful and semantically enriched for embedded knowledge sharing. Minimum 
Information Required in the Annotation of Models (MIRIAM) is a standardized set of metadata 
developed by the SBML community to facilitate the unified curation process of biological 
systems. SBML models the constituents of many components, such as function definitions, unit 
definitions, compartments, species, complexes and reactions etc. In next section System biology 
graphical notation will be discussed.  
3.10.2 Systems biology graphical notation (SBGN): 
Systems Biology Graphical Notation (SBGN) is a graphical representation format developed by 
modelers, biochemists, and computer scientists [171].The proposed usage of SBGN languages is 
to store, exchange, and reuse information about signaling pathways and gene regulatory 
networks. It has also been used in molecular interaction maps such as rheumatoid arthritis map 
[172]. SBGN has a simple syntax and easily understood semantics, thus it is one of the most 
widely used notations in systems biology (Figure 3.4).  
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Figure 3.4: Example of SBGN Entity Relationship map [173]. 
 
3.10.3 Biological pathway exchange (BioPax): 
Biological Pathway Exchange (BioPax) is a representative language for pathways. It is based on 
RDF/OWL, and as the name implies, it facilitates the exchange of pathway data. Exchange of 
pathway data is necessary to attain collective knowledge sets scattered throughout different 
databases and which may exist in incompatible formats. BioPax provides an easy way to 
accomplish different pathway data tasks such as gathering data, indexing data, data interpretation 
and data sharing. With the support of BioPax, thousands of pathways have been organized by 
millions of interactions found in many organisms, making them computable. Many online 
databases offer BioPax export, including Reactome [174], BioCyc [175], BioModels [170], 
Pathway Commons [176], and WikiPathways [177] are among many others. It is also supported 
by various tools such as  Paxtools [178], Systems Biology Linker [179], ChiBE [180], BioPax 
validator [181] etc. 
3.10.4 Biological expression language (BEL): 
Biological expression language (BEL) is a relatively newly formed language; it represents 
scientific findings in a computable format. BEL has additional capabilities to capture contextual, 
causal, or correlative relationships. It also supports embedding observations and published 
evidence to provide a broad contextual knowledge within a model. The knowledge can be 
included during model development to facilitate qualitative modeling of biological processes. 
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BEL also supports automated reasoning methods such as reverse causal reasoning [182]. The 
enriched models developed in BEL are called Knowledge Assembly Models (KAM). Since BEL 
is a recently launched language, the numbers of applications are limited; thus a framework, 
which can process computable knowledge models, BEL Framework, has been designed. Like 
SBML and BioPax communities, a dynamic community is working together on the BEL 
framework to improve its functionality and enhance its capabilities. Figure 3.5 shows a simple 
BEL model with different reactions.  
 
 
Figure 3.5: Example of BEL Model with different reactions. 
 
A qualitative modeling approach to model the disease is agent based modeling which has 
recently gained popularity and fulfills our requirements to model some aspects of MS.  
3.11 Agent based modeling and its application in biomedicine: 
Agent based modeling (ABM) is another approach to model complex systems; it is also known 
as individual based modeling. In this approach, each entity or agent is individually controlled by 
different parameters. It therefore has the advantage of providing attributes specific to a specific 
agent, depending upon the interactions of that agent with other agents as well as with the local 
environment. The power of individuality in this approach can be extensively used in systems 
biology, as in biology each cell or molecule has a specific role. Take, for example, antigens and 
antibodies; without describing their specific features as molecules, it would be much more 
complicated to simulate an environment in which they play an important role. Although an agent 
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can represent a molecule, a cell or a complex, it is most commonly recognized and practiced that 
an agent represents a cell [183]. A typical ABM simulation would be cells (agents) interacting 
with each other in the local environment according to predefined rules, which are usually formed 
from knowledge gained via experiments and studies that is then translated into computational 
algorithms. Based on those rules, the output of the system will be justified; and if the relevant 
details are not sufficiently encoded, then the system may not provide the identical results. The 
results may vary from the encoded knowledge, thus including an iterative process to enrich the 
rules is a mandatory step for ABM. The data to feed those rules could come from in-vitro, in-
vivo or any other experiments and studies; however, the data must be validated first. ABM has 
been used in the modeling of different diseases, one of which is cancer. ABM was also used to 
simulate both the growth of a brain tumor [184] and the role of heterogeneity in drug resistance 
[185].    
3.12 Modeling neurological diseases and particularly MS: 
As previously discussed, the brain is one of the most complex structures of the universe; thus, in 
order to model that level of complexity, a framework which could handle a similar level of 
complexity is needed. Systems biology provides that multi-level platform to integrate, analyze, 
and simulate models and datasets from different –omics studies. In recent times, neuroscientists 
have worked only with reductionist approaches by classifying the brain based on functionality, 
cellular composition, and parts. Even though a reductionist approach yielded some success, it is 
certainly not the way forward in finding a cure for multifactorial neurological diseases. For 
example, one cannot study memory, learning, and behavior by only observing neurons or any 
other individual cell type of the brain. Many fields such as neuroinformatics, computational 
neuroscience, and neurophysiology aim to decode brain functionality. These fields are shifting 
gradually towards systematic approaches, but they are not yet considered to be part of systems 
biology [186]. The ultimate objective of systems biology in neurodegenerative diseases is to find 
pathways involved in disease pathogenesis; this would be done by analyzing networks 
constructed based on different datasets e.g. gene expression, proteomic, and neurobiological 
experiments designed to aid in drug discovery. Many neurological disorders’ models have been 
developed already, e.g. Alzheimer’s disease model [187,188] and Parkinson’s disease model 
[188]. 
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3.13 MS disease modeling: 
As discussed in the previous chapter, MS is a complex disease, with heterogeneity being one of 
its most complicated aspects. The heterogeneity of the disease has been modeled extensively, 
biologically (as shown in table 3.6) [189], but only with limited scope computationally (e.g. 
using stochastic Petri nets [190] and regression models [191]). 
 
 
Model system Strain: antigen 
Clinical course 
Relapsing–remitting Wild type mice SJL/J: PLP131-151 
 
Transgenic TCRMOG SJL/J: MOG92-106 (spontaneous) 
 
Wild type mice, 
adjuvant specific 
C57BL/6:MOG35-55 
(adjuvant Quil A)  
Wild type mice, antigen/adjuvant dose specific C57BL/6: MOG35-55 
(low dose) 
Secondary progressive Wild type mice Biozzi ABH: spinal cord homogenate 
Wild type mice NOD: MOG35-55 
Lesion localization 
Spinal cord Most EAE models 
 
Opticospinal Transgenic TCRMOG x IgHMOG C57BL/6: MOG 
(spontaneous) 
Brain 
(+ spinal cord) 
IFNγ or IFNγR deficiency Multiple 
Wild type mice CBA/J: PLP190-209 
Wild type mice C3H/Hej: PLP190-209 
Wild type mice C3HeB/Fej: MOG97-114 
Transgenic TCRMOG SJL/J: MOG92-106 (spontaneous) 
Wild type mice 
(CD8 T cell clones) 
C3H/Fej: MBP79-87 
 
Pathological pattern 
Pattern I/II Most CD4-mediated EAE models 
 
Pattern III/IV Wild type mice 
(CD8 T cell clones) 
C3H/Fej: MBP79-87 
Cuprizone-induced demyelination C57BL/6, Swiss Webster 
TMEV-induced demyelination SJL/J 
Table 3.6: Various Model systems used for MS, edited version of [189]. 
 
The MS models available so far do not illustrate a broad picture of the disease, while there are 
comprehensive models available already for other neurological diseases. Thus far, there is no MS 
computational model which collectively describes the disease’s mechanism, the interacting 
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molecules in certain phenotypes, and the pathways involved in the disease’s processes. The 
following points are the main reasons to model MS: 
● To more effectively utilize the large and growing body of literature on the disease, 
which is currently very difficult to follow or use to gain an overview of the 
disease’s mechanisms 
● To organize and clarify the heterogenic aspects of the disease, which would help 
answer questions pertaining to certain disease subtypes and mechanisms 
● To identify and establish hubs of molecular interactions, key players in different 
disease processes, and other important pathways 
● To assist in the discovery of potential biomarkers and drug targets 
Various different approaches and methodologies have been used to model MS. Statistical 
modeling and Bayesian approaches have been proposed and applied in the classic manner to 
model the disease course and the heterogeneity of MS. Some of the examples of said approaches 
are nonlinear model of MS disease [192], and modeling time series of MS disease course [193]. 
Modeling has also been used in a longitudinal study of RRMS to illustrate the prevalent physical 
inactivity due to disease severity [194]. In another, similar longitudinal study, flexible modeling 
was used to measure the association of past relapses and disability occurrence in RRMS in order 
to help establish a prognosis of disability and disease progression [195]. Markov models have 
also been developed to link MS disease progression with age and to predict disability progression 
[196,197]. The Bayesian approach, using Expanded Disability Status Scale (EDSS), has been 
used to model disability progression and accumulation in MS [198]. A best-fitting model was 
also developed, longitudinally, for disease progression based on EDSS observations [199]. 
Binomial regression models and other statistical modeling approaches were used to compare the 
efficacy of different drugs (fingolimod, teriflunomide and dimethyl fumarate); it has been shown 
that fingolimod is more efficacious than the other two drugs [200].  
Pennisi et al., [201] developed an agent-based model which demonstrates the oscillatory 
behavior of RRMS, using virtual patient data, and which illustrates the protective role of vitamin 
D in MS [202]. In addition, an extended model was developed to emphasize the potential role of 
blood brain barrier in treatment of the disease [203]. MRIs and image data were used to develop 
a model of brain atrophy which correlate deep grey matter atrophy with white matter 
abnormalities and cognitive functions impairment in RRMS [204]. A lesion formation model 
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was also developed based on MRI data over the period of one year and analyze different patterns 
of T2 lesions [205]. Another model shows the pattern of depressive mood in RRMS over the 
period of 2.5 years, showing that certain factors such as marriage, older age, employment, and 
physical activity play a significant role in depression symptoms’ development [206]. As far as 
the author’s knowledge, no model of MS using systems biology approaches or molecular 
interaction maps of the disease is currently available; thus, our work is first of its kind and novel 
in its direction. 
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4 Chapter 4: Methodology 
The methodology section has been split into the following two parts due to the different scopes 
of the work: 
• Information retrieval and representation 
• Modeling of MS disease 
4.1 Information retrieval and representation: 
The overall accomplishment of the work of information retrieval and representation is to build a 
functional MS ontology as per the standards of basic formal ontology (BFO) [207], which could 
support information retrieval and analysis, and integrate in SCAIView [28]. To accomplish this 
task, a methodology for semi-automated enrichment and translating ontologies was derived [29] 
and a program to develop ontologies with associated metadata [208] was developed. In addition 
to integration into a biomedical search engine, the ontology has also been used to retrieve clinical 
trial records for electronic health record (EHR) mining and to find co-stimulatory pathways in 
different neurodegenerative diseases (details in results section). Following are the steps which 
have been followed and the method used to achieve these results. All the relevant work has been 
published.  
The first step in modeling a disease is to have access to relevant data associated with the disease 
across different resources e.g. clinical data, scientific literature and drug databases. A recent 
issue of Nucleic Acids Research reported a collection of 1,552 molecular biology databases 
[209]. In certain sub-domains of molecular biology, the data availability is not the issue but 
rather interpreting it; for example, modern -omics technologies produce a high volume of data 
with each experiment. Ontologies play a crucial role in integrating different databases and 
retrieving relevant knowledge. Disease ontologies have recently been used to represent domain 
specific knowledge [210,211]. These ontologies help to retrieve and gather all the relevant 
information about the disease from different platforms e.g. literature from PubMed, clinical 
information from EHR, and drug-specific knowledge from DrugBank and other domain-specific 
databases.  
The objective of this section is to develop an MS disease ontology which could support the 
integration of disease-specific knowledge across different platforms and answer complex 
queries. The queries would be much more complicated than simply typing the disease term into 
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PubMed, as the ontology would facilitate precise information retrieval due to the associated 
semantics. In the following sections, I describe our methodology of developing an ontology and 
enriching it with one of the largest biomedical repositories available.  
4.1.1 Foundational work for ontology development: 
The first step to develop ontology was to collect all the concepts associated with the disease. For 
this two different approaches have been used. The first was manual collection of the disease-
specific concepts by e.g. reading literature and websites in order to gather the concepts; for 
example,  gathering all the relevant concepts mentioned on the website of Encyclopedia of 
Multiple Sclerosis [212]. In addition to looking at only one particular website, we were interested 
to do the concept collection task automatically and to generate a relevant text corpus from the 
internet so that corpus could be processed offline, and concepts could be tagged and extracted by 
using natural language processing (NLP) tools. With this purpose in mind, a methodology has 
been derived [30] by which one can rapidly generate a clean corpus from different websites. The 
description of the methodology is discussed later in this chapter.   
The second approach was to use NLP tools (Named Entity Recognition) on some of the MS 
books, tag all the biological concepts, and then determine their role in the disease. We used the 
Temis Luxid tool (version 6) [6] and its biological entity recognition cartridge, developed by the 
Fraunhofer institute, to process the books. The tool chosen to develop the ontology was Protégé 
(version 3.3.1) [12], because of its usability and variety of available plug-ins. Following 
hardware specifications were used for all the work: Dell Latitude E4310 - Core i5 Notebook with 
Dual core processor, 4 gigabytes RAM, and 120 gigabytes hard drive. 
After collecting the disease-specific concepts, we wanted to have all the synonyms associated 
with those concepts in order to broaden the coverage of the ontology. Synonym enrichment 
prevents information loss due to the various naming conventions in different literature sources; 
for example, Interleukin-17 could be written as IL-17 or IL17. The ontology must be rich enough 
to have as many synonyms of each molecule associated with the disease as possible, thus Unified 
Medical Language Systems (UMLS) was selected. 
Ontology enrichment is a process of embedding metadata associated with the concepts defined in 
ontology. The specific metadata or attributes are added to have a unique set of concepts in an 
ontology specified for a domain. Different types of attributes are added to cover different 
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aspects; definitions are added to have a common understanding of concepts; synonyms are added 
to have a broad coverage of ontology; and references are given to provide the source of 
knowledge. In addition, there could be as many attributes as developer wants e.g. date, 
comments, language, label, contributor, creator, identifier, etc. Manual ontology enrichment has 
several disadvantages which deter its usage being common. It requires a great deal of human 
effort and time, making it less attractive for scientists. Additionally, searching different sources 
for different concepts could lead to disagreements among concepts within an ontology and limit 
its application on a specific domain. There are few automated ontology enrichment tools, and 
these require technical expertise of computing and natural language processing; thus they are not 
a first choice for biologists. In addition, since most of the tools work on a corpus to generate a 
hierarchical ontology, the results could vary significantly based on the content of the corpus. 
These tools can help to develop de novo ontologies, but they may not be appropriate for 
enriching a domain-specific ontology. To have a harmonized ontology it is a good practice to 
retrieve attributes of concepts from a unified and broadly accepted database. Using automated 
tools to query the repository could reduce human errors and make this repetitive and time-
consuming task easier. Further, it is also a good practice to assign unique identifiers to each 
concept in order to make them interoperable with and semantically relevant to other ontologies.  
UMLS is a very large repository of medical concepts which integrates and streamlines many 
health vocabularies to enable interoperability among them. UMLS has more than 100 source 
vocabularies [213] and it has been reported that the 2009AB release of the UMLS Metathesaurus 
contained 2,120,271 biomedical concepts and 5,305,932 unique terms [16]. Two areas of its 
usage are in electronic health records software development and by health-related language 
translators. UMLS deals with the complexity of different biomedical concepts by assigning a 
unique identifier to them, called a Concept Unique Identifier (CUI). CUIs have a unique alpha-
numeric (C0000000) format which is consistent, though the sources of the concepts may differ. 
CUIs are being used to map concepts from different sources to UMLS. Mapping ontology 
concepts to UMLS CUIs makes them more interoperable, accessible and provides a common 
understanding of the concepts. By using UMLS CUIs, additional metadata of the concepts 
(definitions, synonyms, etc.) could also be integrated.  
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4.1.1.1 Setting up UMLS locally: 
UMLS can be queried via the web; however, in order to query hundreds of concepts it was 
necessary to set up a local instance of UMLS. It is possible to load UMLS onto a local database 
via various configuration scripts i.e. MySQL, Oracle, or Microsoft Access [214], and thus 
expedite data querying and retrieval. MySQL Server 5.5 has been used because of the stability 
and free availability. The installation and configuration were done following the guidelines given 
at [215]. The UMLS database (when implemented on MySQL) is approximately 26 gigabytes, 
which is fairly large for the average personal computer. This contrasts with the database size 
restrictions in some programs such as Microsoft Access, which can only create a database with 
the maximum size of 2 gigabytes [216]. Due to the large size of UMLS, the performance of the 
system running locally is often compromised and manual querying is not considered a preferred 
choice. One solution for this problem is to set up an automated loop to query, retrieve, and store 
data, thereby repeatedly and regularly querying hundreds of concepts in a short time. This can be 
done via automated workflow programs e.g. Taverna [217] and Konstanz Information Miner 
(KNIME) [5] and discussed in details in following sections.  
4.1.1.2 Connecting KNIME to MySQL: 
KNIME is an open source, easy to use and graphical user interface workbench for different data 
analytics processes. It provides a broad range of nodes and plug-ins to connect to web services, 
run scripts and execute external applications within the workbench [5]. We wanted to query 
UMLS implemented on MySQL database, and with KNIME (version 2.8) it was relatively easy 
to connect to different databases including Oracle, SQLite or any other JDBC/ODBC-compliant 
databases by using “Database reader node” (Table 4.1). The connector “mysql-connector-java-
5.1.12-bin.jar” was downloaded from MySQL website [218]. 
 
Configuration of KNIME “Database reader node” 
Database Driver: Com.mysql.jdbc.Driver 
Database URL: Jdbc:mysql://localhost:3306/umls 
User Name: Root 
Password: Root 
Table 4.1: MySQL connection settings in KNIME “Database reader node”. 
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4.1.1.3 Automated data retrieval from UMLS: 
The list of disease-specific concepts gathered from the processed corpus of online MS 
Encyclopedia and MS books was used to query the UMLS via an automated workflow of 
KNIME (Figure 4.1). The starting node “XLS reader” reads the list of concepts and formulates it 
as KNIME standard table output. The second node “TableRow to Variable Loop Start” uses each 
row of a table to define a variable for loop iteration. The third node “Database Reader” connects 
to the database (UMLS) and queries with the variable provided in the previous step (Node 2). 
The fourth node “Loop End” continues the loop until the last row of the file and ends the loop. 
The last node “CSV writer” writes the output as comma-separated values (CSV) file. This 
automated approach queried each concept one by one and gathered the associated data into an 
output file. 
Most of the retrieved results were accurate because quotation marks were used for more than one 
word concepts and acronyms were avoided. After the data retrieval, we wanted to integrate the 
automatically retrieved results into our ontology, and this was done by using OntoFast (version 
01) [208].  
 
 
Figure 4.1: KNIME workflow to automate the querying process from MySQL (Loaded with UMLS). (From left) The first 
node reads the Excel table, second node creates a loop, third node reads the each item of the loop and queries the databse, 
fourth node repeats the loop until it ends, and fifth node writes all the data to CSV file.  
 
4.1.2 Automated ontology translation from UMLS: 
The limiting factor of ontologies’ usage is their availability in only few languages. Most of the 
ontologies are available only in English, which restricts their application on English datasets 
only. The biomedical domain is one of the largest domains which has many well-designed 
ontologies as well as a widespread application. Bioportal [219], a biomedical ontology database, 
has 370 ontologies at the time of this writing. As discussed above, most of them are only 
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available in English, thus it is practically impossible to use them in conjunction with other 
language datasets to retrieve information from other language repositories. Here we describe our 
use case of ontology enrichment with the Spanish translations of concepts by using UMLS in a 
semi-automated way. The aim of our work was to extract knowledge from the EHR dataset, 
which was only available in the Spanish language.  
There are some translation tools already available which could translate an ontology into another 
language. One such tool is LabelTranslator [220], which translates via Google translate and other 
web services, and requires manual selection of the individual, respective translated concepts. On 
the contrary, our system offers a much easier integration of translated concepts queried from an 
authentic domain source. Furthermore, our approach is very easy to use and requires only copy-
and-paste to expand the ontology with concepts available in other languages. Figure 4.2 shows 
the overall outline of our approach for translating concepts and enriching ontology with them. 
 
 
Figure 4.2: Overall outline of the Ontology enrichment and translation. Left side workflow starts with the configuration 
of the UMLS system while right side starts from Ontology file. After extracting all the ontology concepts, they can be 
queried over UMLS to retrieve associated metadata. Retrieved concepts can be simply embedded into ontology for 
enrichment or used further to get relevant concepts in other languages.  
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In addition to the automated enrichment and translation methodology, a program has been 
developed to quickly develop ontologies with all their associated metadata. Details of the 
program will be discussed in results section of the thesis.  
As discussed above, In addition to text mining MS books and scientific papers, another approach 
to gather concepts is to generate datasets from MS-relevant websites by mining the web and then 
processing those datasets with NLP tools. A methodology has been derived to obtain clean 
datasets from the web, which were scattered across different web pages, in a short amount of 
time. 
4.1.3 Corpus generation from the web: 
This method requires a plug-in oriented web browser e.g. Mozilla Firefox [221] or Google 
Chrome [222] as well as the DownThemAll plug-in [223], the Link Gopher plug-in [224] or any 
variation of GREP Program [225]. DownThemALL is a browser extension which can download 
hundreds of documents in one go. GREP is a widely used utility program which provides 
different functionalities, but for the task it was used only to filter results.  
All the programs need to be installed on a PC, and then clean datasets from different websites 
can be downloaded in a relatively short period of time and with little effort. Please note that 
some websites may prevent massive downloading and are only available for human access, thus 
prior permission may be required. This technique has been used on LinkedCT.org, one of the 
largest semantic repositories of clinical trials, which processes ClinicalTrials.gov and transforms 
it as RDF/XML. For this work, following versions of software were used: 
- Mozilla Firefox version 17 
- DownThemAll version 2.0.16.1-signed 
- Link Gopher version 1.3.2.1-signed.1-signed 
The initial steps of the corpora creation require identification of the pattern of the hyperlinks of 
the data you are interested in. If the links are available on one page, then DownThemAll can 
automatically detect them and you can start downloading the dataset or web pages instantly. If 
the actual data is beneath a few layers of web pages, then you can download first the source 
page(s) and then the actual data itself. This is done by combining all of the source html pages 
and extracting hyperlinks via Link Gopher or by using the GREP program. The good feature of 
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GREP is that it will also bring the data within the proximity of up to 5 lines from the actual 
search term, which could help with understanding the pattern of hyperlinks.  
 
 
Figure 4.3: A perspective from user interface. The actual dataset was concealed below 3 web pages (shown in green), after 
search results are displayed on the website.  
 
In the presented scenario, the dataset was beneath many other pages, and the hyperlinks of the 
actual files were scattered across different pages. As mentioned above, DownThemAll was used 
to collect the top pages (all three layers) and different terms associated with the same disease 
(Figure 4.3). The first layer contained the name of the disease with different orders and 
synonyms. There were 11 pages on the second layer which referred to 175 pages (third layer) of 
relevant data files, but in html format. The third layer also contained the link to the actual data 
file (in RDF format) as a hyperlink. All 175 pages were collected and patterns of hyperlinks, 
pointing to the actual data files, were observed. The manual work would have taken too long for 
this task, as one would have had to click forward and backward hundreds of times repetitively 
for quite some time. With the help of tools mentioned above, the task was done relatively 
quickly. This task helped us to collect MS relevant concepts from web, which were not found in 
MS books e.g. Turmeric.  
After ontology development and enrichment, the next step was to develop the disease model and 
then make this model available within the scientific community, thus enabling iterative updates. 
It is worth mentioning that the MS ontology has been integrated into SCAIView, a semantic 
biomedical search engine. The concepts which were used in ontology development were also 
used to build disease models.  
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4.2 Modeling of MS disease: 
The second part of our methodology discusses the approaches of modeling that we used. We 
used a bottom-up systems biology approach to develop a molecular interaction map of the 
disease. We used a semantic biomedical search engine (SCAIView) to rank molecular entities 
associated with the disease. The aim of the model is to have a graphic representation of the 
disease mechanism, and by looking at it one can immediately get to know important molecules, 
drugs acting on certain pathways, and phenotypes caused by different interactions. This map 
must provide an established knowledge of the disease, so that one does not need to sift through 
thousands of published papers or a large body of literature. The semantic tool, SCAIView, 
processes all the PubMed citations and provides filtration of results based on certain terms e.g. 
human genes and proteins etc. (Figure 4.4). This makes it convenient to distinguish knowledge 
between humans or any other organisms.  
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Figure 4.4: SCAIView user interface and top ranked results based on Relative Entropy are shown. Top left shows the 
search term “multiple sclerosis” and filter “Human Genes / Proteins”. 
 
The platform chosen to model this knowledge is a Systems Biology Workbench tool called 
CellDesigner (version 4.1) [1]. Other tools were also evaluated, including Cytoscape[226], but 
CellDesigner was preferred due to its various features. CellDesigner is a state-of-the-art 
structured diagram editor for drawing gene-regulatory and biochemical networks. Its intuitive 
user interface helps draw diagrams in rich graphical representation with personalized design. 
Networks are constructed based on a state transition diagram proposed by Kitano et al. [2]. 
Recent versions further comply with SBGN process description diagrams [227]. Designed as a 
standalone tool, this powerful software is network-aware and therefore can connect to several 
major databases (DBGET[228], SGD[229], iHOP[230], Genome Network Platform[231], 
PubMed[232], Entrez Gene[233], SABIO-RK[234]) as well as retrieve models from 
BioModels.net[235]. CellDesigner lacks the wiki integration of PathVisio[236], has limited 
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network analysis capabilities, and has fewer available plug-ins than Cytoscape. Furthermore, its 
source code is not available. Despite these shortcomings, the appealing user interface, the native 
support for SBML and the straight integration with the System Biology Workbench [237] were 
sufficient reasons for making CellDesigner our final choice as the tool to be used for our work. 
CellDesigner uses MIRIAM [8] for annotation of the SBML models.  The version of the 
MIRIAM database has been extended with additional data types for storing sentences, for 
annotating with UMLS and with MEDDRA [238].  
4.2.1 Molecular interaction map of MS: 
After developing the ontology, some of the concepts which were used in ontology have been 
used further to develop molecular interaction map of MS. As discussed above, the objective of 
the work was to have a disease map with sufficient details of the disease mechanisms, drugs 
targeting different pathways, and the clinical outcome of the interaction between different 
molecular entities. One specific requirement was to have a supporting sentence behind each edge 
of interaction with the PubMed-ID (PMID) or source of that sentence.  
4.2.1.1 Selection of seed entities: 
The topmost occurring entities associated with the search term “Multiple sclerosis” and “Human 
genes / proteins” (Figure 4.4) in the SCAIView have been selected. The selection of proteins and 
genes was made based on the Relative Entropy score (a confidence measure) above 0.050. Then 
all the abstracts associated with the molecules and MS disease association with any of the 
molecules were read to find an interaction. The molecules which were not in the ranking, but 
were mentioned in the abstract as interacting with one of the ranked molecules were also 
extracted and used in interaction map. 
4.2.1.2 Selection of corpus: 
A corpus of text has been collected after reading the abstracts. The corpus (collection of abstracts 
from which the sentences and relations were taken) was collected by considering only those 
abstracts which contained “Multiple Sclerosis” or its animal model “Experimental Autoimmune 
Encephalomyelitis” and had co-occurrence with entities ranked by higher relative entropy in 
SCAIView. The corpus must also contain either information on the molecules involved in certain 
disease states, or on their interaction manner in relation to disease behavior changes (either 
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increasing the likelihood of disease pathogenesis or suppressing the phenotypes associated with a 
disease state). 
4.2.1.3 Corpus annotation: 
Sentences from the corpus were manually tagged and extracted where a clear statement of 
relation between any two entities (gene, protein, drug, simple molecule or phenotype) was 
mentioned. The entities were standardized by being given a UMLS CUI, in addition to the name 
mentioned in literature. The CUIs were also stored under the MIRIAM section of each node of 
the map. 
4.2.1.4 Disease model development: 
The disease model was developed by linking the nodes (molecular entities, drugs, phenotypes 
etc) with edges supported by sentences, which were embedded within the model under each 
edge. This embedding also contained the source information or PMID to track back to the 
original abstract. The local version of CellDesigner (4.1) was extended to accumulate text 
annotation.  To re-use this embedded knowledge and make it available for the scientific 
community, a plug-in was developed to transform the disease model into a Mediawiki 
knowledge base [13]. The model can be curated by groups using Payao web portal [239]. 
4.2.1.5 Validation of model: 
Validation of model was done by reading reviews which were published recently about the MS 
disease and those were: 
(1) Therapy of MS [240] 
(2) Multiple sclerosis therapies: molecular mechanisms and future [241] 
(3) Multiple Sclerosis: risk factors, prodromes, and potential causal pathways [242].  
The validation was needed as one could argue that most of the co-occurring molecules associated 
with MS in SCAIView or in scientific literature are generally the longer known molecules. By 
using that approach one could easily miss the novel and recent discoveries. The recent 
discoveries may not be included in as many scientific publications, as compared to a molecule 
discovered 10-20 years ago. So, recently published reviews were found which covered different 
aspects of MS, and compared their findings with our model. Newly found entities in reviews 
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were added by searching entities (e.g. xxx) with “Multiple sclerosis” i.e. “Multiple sclerosis + 
xxx” in SCAIView and the retrieved data was added to the disease model.  
The clinical aspect of the disease and drugs data were missing from the model as so far the 
knowledge was only extracted from established scientific publications thus next clinical data and 
drugs mode of action were overlaid on the model.  
4.2.2 Overlaying clinical trials and DrugBank data: 
The data from public and commercial clinical trial datasets were integrated into the model. A 
commercial dataset was taken from Trialtrove, which is one of the largest repositories of clinical 
trials [243]. 2,412 clinical trials were found in Trialtrove by using the search term “Multiple 
Sclerosis” under the category of therapeutic area “CNS” (Figure 4.5).  
 
 
Figure 4.5: Clinical trials associated with Multiple Sclerosis in a commercial database [243]. 
 
Then molecules associated with RRMS, a subtype of MS, were filtered out and their associations 
were studied. In addition to Trialtrove clinical trial data, the public clinical trials dataset from the 
National Multiple Sclerosis Society’s (NMSS) [244] was also obtained and processed. The 
NMSS clinical trial dataset is unique in a way that it is the only public dataset (to the author’s 
knowledge) which contains the results section and name of the publications (Figure 4.6).  
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Figure 4.6: Snippet of a clinical trial summary record available on the NMSS dataset [244]. 
 
DrugBank RDF dataset [245] was used to extract MS drugs’ mode of action and the molecules 
which the drugs act upon. This knowledge was also mapped into the disease map.  
One challenging aspect of MS is the different disease progression patterns of its subtypes. To 
reveal the patterns behind that aspect, the biomarkers specific to each subtypes were extracted 
from literature so the specific molecules for each subtype can be revealed. 
4.2.3 Time series of MS disease progression: 
The complexity behind MS disease subtypes and their progression may be discovered by 
identifying biomarkers specific to each disease subtype, segregate different disease subtypes, and 
isolate and mark the clinical endpoints of a particular disease subtype in chronological order, 
with the help of associated biomarkers. A rigorous search was performed to select a specific 
body of literature, including full text research papers. An advanced text mining tool Temis Luxid 
(version 6) [246] was used, as well as text mentioning the association of any molecules and their 
significance to the disease subtype was manually extracted. After careful selection of contents, 
560 research papers have been selected.  
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4.2.3.1 Disease segregation based on biomarkers and therapeutic agents: 
The results and observations of patients in different disease stages i.e. Clinical Isolated 
Syndrome - CIS (even though it is not considered as disease subtype, it may be considered as 
prediction stage of the disease), RRMS, SPMS, PPMS and PRMS have been segregated. 
One of the challenges in the work was to find a time-dependent shifting of molecular behavior in 
relation to disease phenotype as well as to find out potential perturbed pathways involved in each 
of the stages. The question has been asked if it is possible to discover a means to control or 
prolong the shifting phase and reduce disease severity by optimizing drug combination. This 
could help us with finding events which cause the disease worsening in different time intervals 
between the different stages. Furthermore, we were also interested to identify biomarkers which 
play a role in acute types and rapid progression of the disease. In addition to the four subtypes of 
MS, we also looked at the molecular mechanism of CIS. CIS is the primary indication before the 
disease starts getting worse, and this is considered one of the basic indicators of the start of 
disease (MS). As mentioned above, it is not a disease sub-type as the occurrence of MS after CIS 
is 50% [86]; however, looking at the biomarkers associated with CIS could help predict the 
possibility of MS occurrence. 
The four subtypes of MS are known, but the longitudinal sequence of the events with respect to 
disease progression is not necessarily linear. Sometimes the course of the disease is aggressive 
and it rapidly changes from one point to another. Some patients experience no PPMS stage, but 
rather progress directly from RRMS to SPMS. As for covering the widely known knowledge and 
patient population, a pattern of linear progression has been considered.  
4.2.3.2 Annotation of the scientific literature: 
Important scientific findings in full research papers (PDF format) were annotated, and 
highlighted text was extracted with Zotero (version 3.0.9) [247]. Interpreted results were 
collected in a Microsoft Excel table and scanned research papers were processed before 
annotation with an optical character recognition (OCR) software. Figure 4.7 shows the text 
snippet of an annotated research paper.  
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Figure 4.7: Example of the annotated Text of a research publication. Different parts of the publications were annotated; 
here the result section is shown. 
 
The output table contains many columns with relevant findings and biomarkers found in 
literature. Data of different biomarker types (discussed in chapter 2) from 560 research papers 
with all MS disease subtypes were extracted. The resultant lists of biomarkers were used to 
develop biomarker molecular interaction maps. The enrichment of those maps was done using 
the Ingenuity Pathway database [4]. Enrichment brought the resulting pathway where those 
molecules play crucial roles. Ranking of pathways was done based on the number of molecules 
involved in each pathway.  
In addition to biomarkers-based segregation, we also separated different disease subtypes based 
on the therapeutic intervention. There are different sets of therapies given to patients at different 
stages of the disease. These are known as different lines of therapies e.g. first line therapy, 
second line therapy etc. The drug regimens were selected based on the severity of the disease, 
and we hypothesized that since there are different pathways involved in each disease subtype, the 
targets being hit by different lines of therapies could also be different. If there is a coherence of 
those pathways, then the perturbed pathways certainly play a role in the disease; this would be an 
affirmation of our findings. To do this we used all FDA approved drugs available for MS and 
found the pathways they are targeting. This was done by constructing each drug network by 
populating the knowledge from Ingenuity pathway database and then mapping those networks to 
pathways.  
After exploring various streams of knowledge of MS disease and laying the foundation of a 
system based on which a knowledge base can be established and simulation can be executed to 
generate hypothesis which may open the frontiers of novel drug targets, the new challenge was to 
have a qualitative model of the disease. The rationale behind developing an agent based model is 
that there is a large body of knowledge available which supports the notion that MS is disease of 
cellular interplay and shift from one cellular population to another may change the pattern of the 
disease. In the introduction part of the thesis, the protective factors and risk factors have been 
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discussed and shown (Figure 2.2). In the next section, we will explore one aspect of cellular 
interplay and their role in disease.   
4.2.4 Agent-based model of Treg-Teff interplay and its role in RRMS: 
Agent-based modeling (ABM) meets the specification required by some of the biological 
mechanisms. The dynamics of certain biological entities can be embedded in ABM, such as 
position, function of time, internal states (e.g. age, active etc) as well as certain interactions such 
as binding, which modifies the behavior of the interacting agents. These dynamics of the global 
system are generated by interactions of all agents in a certain environment. ABM deals with 
heterogeneity and spatial issues of agents, and it is relatively easy to describe the complex rules 
assigned to the agents. Agent-based models have been used for simulating many diseases e.g. 
HIV [248–250], mammary carcinoma and lung metastases [251,252], atherosclerosis [253] as 
well as the cell-based immune response to cancer cell antigen presentation [254]. Since there 
were many disease-specific agent-based models, ABM has been selected to model the interplay 
between T-regulatory (Treg) and T-effector (Teff) cells and, additionally, their role in RRMS 
and causing relapses. To develop a model of RRMS, following assumptions were made based on 
the available experimental findings:  
(A) The interplay amongst Treg-Teff cells and the up-regulation of Treg cells by Teff cell 
signaling [255]. The imbalance between the two cell types has been shown to play a crucial role 
in both MS and Type 1 diabetes [256,257].  
(B) The inhibition of Teff cells by Treg cells by means of cell to cell contact inhibition 
[258] and immunosuppressive cytokine secretion [259].  
(C) The inflammation caused by EBV, as it has a role in modulating the human immune 
system and is considered to be an important factor in MS pathogenesis  [84].  
(D) The role of biomimicry; EBV-specific T cells cross-react with auto-antigens such as 
Myelin Basic Protein (MBP) and destroy it.  
(E) The correlation between relapse and neural damage, as some studies have shown  the 
presence of biomarkers specific to axonal damage and myelin damage (NFL and MBP) to be 
higher in RRMS patients [260]. 
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We used NetLogo programming language [261] and software suite (version 5.0.1), which 
implements an  agent-based oriented programming language. It is an excellent option to model 
and simulate multi-agent environments and complex systems.  
4.2.4.1 The model and simulation: 
The model was developed in NetLogo using the following agents (called turtles in NetLogo): 
• Epstein Barr Virus (EBV) 
• Treg Cells 
• Teff Cells 
The model’s environment was represented as a myelin sheath. Myelin is considered to be the 
place where all the interactions of cells and viruses take place. In the interest of simplicity, the 
blood-brain barrier was not shown. The following are the major events of the simulation: 
4.2.4.2 Role of EBV: 
EBV virus causes infection and invokes mimicry which activates the auto-reactive Teff cells and 
Treg cells [262]. Due to the antigenic mimicry of EBV epitope, Teff cells attack the myelin as if 
it were EBV. The viruses themselves do not interact with the myelin patches. A virus has a 
radius (virus_radius), and within this radius T cells can become activated; the virus will then be 
eliminated.  
4.2.4.3 Role of Treg cells: 
There are two states of Treg cells in the model, resting and activated. Resting cells do not 
interact with Teff cells; but rather, they become activated after EBV infection. Activated Treg 
cells can suppress Teff cells and duplicate themselves in response to positive feedback. The 
suppression of Teff cells occurs via different cytokines’ signals released by Treg cells. In the 
interest of simplicity, the various cytokines were not modeled. The duplicated Treg cells have a 
life reduced by half, and the new cells are active and present in the vicinity of the same myelin 
patch. 
4.2.4.4 Role of Teff cells: 
As with Treg cells, there are two states of Teff cells in the model, resting and activated. Resting 
Teff cells do not interact with myelin or Treg cells. They become activated once they interact 
with the EBV. Activated Teff cells can damage myelin, due to mimicry, and duplicate. If 
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activated Teff cells are in a patch with the myelin quantity higher than 0, then Teff cells attack 
the myelin and reduce the amount of myelin and duplicate themselves. If the myelin quantity is 
0, then Teff will not be able to duplicate. The duplicated Teff cells will have their life reduced by 
half, and the new cells will be active and present in the same patch’s vicinity. 
Parameter Meaning 
treg_radius max visibility radius of Treg 
eff_dup max. duplication rate of Teff 
init_mye initial quantity of myelin per patch 
eat_mye quantity of myelin destroyed by Teff 
pt max. duplication rate of Treg 
patch_density max. no of entities per patch allowed to have duplication 
Teff_life Teff mean half-life 
Treg_life Treg mean half-life 
Table 4.2: Parameter used for the model and their meaning. 
 
4.2.4.5 Role of environment or myelin: 
The environment (the patches) represents a small portion of white matter and is initially grey in 
color. The variable used for this parameter is init_mye. The damaged caused by Teff cells to the 
myelin is categorized as recoverable or non-recoverable. The recoverable patch is also initially 
grey in color, while non-recoverable damage is black in color. The variable to define the damage 
is called ate_mye. The damage is either recoverable or unrecoverable, depending upon the 
availability of myelin in the vicinity as per rec_mye rate at every time-stamp; otherwise, the 
damage is unrecoverable. The recovery of myelin is based on the repair mechanism of 
Oligodendrocytes [263].  The time-stamp was given as 2.4 hours, as it allows a good degree of 
granularity to simulate single relapse and also allows reasonable disease progression in a 
simulated time span of five years (18,250 times). A random number is generated in the start of 
simulation and the value is then set to number of agents to have a randomized simulation. All 
agents are free to move and interact with each other.  
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5 Chapter 5: Results 
 
In agreement with the methodology section, the results section is also divided into the following 
two main parts: 
• Information retrieval and representation 
• Modeling of MS disease 
5.1 Information retrieval and representation: 
5.1.1 Ontology Development: 
The purpose of MS ontology development was to have a unique set of terms associated with the 
disease to help integrate knowledge scattered on different platforms, and to create a common and 
unified understanding of the disease-relevant concepts. The scope of the ontology was to use it 
for disease specific information extraction and to model MS disease. The MS ontology is 
developed using standard basic formal ontology framework. The main classes of ontology are: 1) 
Clinical Presentations 2) Risk Factors 3) Molecular Entities. In addition to those classes there are 
also concepts about demographics and the social impact of the disease. There are 1,170 concepts 
in the ontology with 7,205 synonyms, which equals roughly six synonyms for each concept 
(Figure 5.1). Most of the concepts are molecular entities because of the application and scope of 
the ontology. A list of MS biomarkers used in ontology are taken from one of the recently 
published papers [106]. The resulting extraction associated with these concepts would be used to 
model the disease mechanism and the role of molecules in it.  
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Figure 5.1: Each concept in ontology contains different types of associated metadata e.g. Definition, Context, Synonyms, 
and Reference. 
 
Due to the large number of synonyms and well defined concepts with standardized identifiers, 
MS ontology (MSO) enables the retrieval of better results. The identifier makes it possible to 
reuse the same ontology across different websites and domains (the identifier is a unique alpha-
numeric code from UMLS) and retrieve specific information from them. MSO also facilitates the 
discovery of co-morbidities associated with the disease, as demonstrated in the research paper 
[28]. Mining PubMed is another application scenario of the ontology. Another application is to 
use the concepts with all the relevant tagged knowledge to develop the molecular interaction map 
of MS. 
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Figure 5.2: The MS Ontology and its application: A) A basic formal ontology integration of MS Ontology and hierarchy 
of the concepts; B) Main classes of the MS Ontology and number of documents retrieved after mining PubMed via 
SCAIView; C) Tagged document after the integration of ontology in the search engine, SCAIView. 
 
Figure 5.2 shows the hierarchy, main classes, and one application scenario of the ontology. The 
knowledge retrieved after integrating ontology into the semantic search engine SCAIView was 
used to model MS interaction map. The integration facilitated to find contextual knowledge of 
molecules and their role in disease mechanisms. 
The enrichment of the ontology was done by using KNIME workflow querying UMLS database. 
In the following section the process has been discussed in details.  
5.1.2 Automated data retrieval from UMLS: 
The goal of this task is to enrich MSO with metadata retrieved from UMLS and to have an 
automated approach to retrieve the synonyms, definitions, and CUIs of the concepts. The 
retrieved data could then be embedded easily into the ontology by using OntoFast [208], which 
enriches the ontology in an automated manner. The proposed solution saves time by allowing 
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users to retrieve data of many concepts automatically instead of doing a manual search. The 
starting point to enrich the ontology is to compile a list of concepts.  Concepts from ontology 
were used to work further, there were more than one thousand concepts (1,170), and retrieving 
their attributes from UMLS database one at a time (or together) in one SQL query would have 
taken too long, as there could be hundreds of synonyms for some concepts. For example, the 
concept “4 Aminopyridine” has 306 synonyms with the language selected as “English” (Table 5. 
1).  
 
CUI String Relation Synonym Language Definition 
C0000477 4 Aminopyridine SY 4 Aminopyridine ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY 4-Aminopyridine ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY Pymadine ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY 4-Pyridinamine ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY Aminopyridine 04 ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY Fampridine ENG Potassium channel blocker,.. 
C0000477 4 Aminopyridine SY 4-AP ENG Potassium channel blocker,.. 
Table 5.1: Some of the synonyms associated with the concept “4 Aminopyridine” retrieved from UMLS with the language 
selected English. Concept Unique Identifier (CUI), relation, and definition of the concept are also shown. 
 
For the automated task KNIME was chosen. KNIME provides an easy way to automate these 
kinds of repetitive tasks, and there are ready-to-use nodes present to retrieve data from different 
databases. To avoid both performance issues with a large SQL query and repetitive manual work, 
a KNIME workflow has been built. The workflow reads each cell in a Microsoft Excel 
spreadsheet, queries the database, stores the retrieved results, and then reads the next cell of the 
Microsoft Excel file. The SQL query of “Database Reader” was modified to retrieve results 
based on a variable of the loop. The following terms were queried: CUI, definition of the 
concept, relation type (in our case Synonym), and language of the concept. The Synonym 
column brought all the variants of the original term, indicated by the abbreviation SY. The 
output of the workflow was a CSV file with different columns containing the queried terms 
(String), CUIs, definitions, relation types and synonyms. As depicted in Table 5.1 for the query 
“4 Aminopyridine”, only the values in the Synonym column of the output table changed. Since 
the relation queried was “SY” (Synonym in UMLS syntax), all the synonyms which had “4 
Aminopyridine” as a heading term and had a relation type SY were retrieved. Repetitive values 
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in columns Term, CUI, Definition, Relation, and Language indicated the attributes of the 
respective value in the SY field. 
5.1.2.1 Evaluation of the system output 
Some concepts were too vague to obtain an accurate retrieval; for example, the retrieved results 
of DC could be either Dendritic cell or Washington D.C., indicating that the queried terms 
should be clearer. In addition, we also noticed that querying with the biological entities i.e. genes 
or protein names generated two different results. One was associated with the gene whereas the 
other was associated with the protein name. Due to this reason, the output needed to be filtered 
depending upon the application scenario of the ontology. Besides that, phonotypical terms such 
as action potential, neurodegeneration, magnetic resonance imaging or drug names e.g. 4-
aminopyridine were non-redundant. Although not all the ontology concepts were present in 
UMLS, most of the retrieved results for the concepts present in UMLS were correct according to 
the manual evaluation. 
5.1.3 Automated Ontology Translation from UMLS: 
By using a similar approach as described above, Spanish synonymous terms were also extracted 
and integrated in the ontology. The ontology was then able to extract knowledge from the 
Spanish text corpus. The semi-automated approach facilitated quicker performance of the task; in 
relatively short time we had an equally rich ontology as existed in the native language. It was 
observed that some molecules’ names did not change, as the molecule names were based on 
different scientific findings. In addition, it was also found that multiple words terms (such as 
experimental autoimmune encephalomyelitis) were difficult to deal with, and that is why it is 
very important to assign CUIs manually before running the translation query. The Spanish terms 
enriched ontology has been used extensively to retrieve data from the Spanish EHR corpus 
(Table 5.2). A similar task can be performed with MeSH terms, and any concept can be 
translated into one or all of the 16 available languages of MeSH terms. The system not only 
works for UMLS, but it is also possible to retrieve data from any other database as the correct 
mapping of identifiers is important.  
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English Terms CUI Spanish Terms Language 
Acetylcholine C0001041 Acetilcolina SPA 
Esophageal Reflux C0017168 Acid reflux SPA 
Homocysteine C0019878 Acido 2-Amino-4-mercaptobutirico SPA 
4-Aminobutyric Acid C0016904 Acido 4-Aminobutirico SPA 
Folic Acid C0016410 Acido Folico SPA 
Acid Synthase, Fatty C0015683 Acido Graso Sintasa SPA 
5-HIAA C0020361 Acido Hidroxiindolacetico SPA 
Actin C0001271 Actina-alfa SPA 
Activation, Lymphocyte C0024262 Activacion de Linfocitos SPA 
Behavior, Sex C0036864 Actividad Sexual SPA 
Hypoesthesia C0020580 Adormecimiento SPA 
Adrenaline C0014563 Adrenalina SPA 
Aphasia C0003537 Afasia SPA 
Agents, Anticholinergic C0242896 Agentes Anticolinergicos SPA 
Agents, Antidepressive C0003289 Agentes Antidepresivos SPA 
Table 5.2: The resulting table after the translation query execution. English term, identifiers, Spanish Terms and 
Language columns are shown. In UMLS syntax, SPA represents Spanish. The important aspect of the retrieval was to 
provide the correct identifier and language of output.  
 
A recently developed tool (OntoFast, discussed below) [208] facilitates ontology enrichment and 
it required minimum efforts to add all the Spanish concepts into a pre-existing ontology. It 
provides an easy-to-use interface and can take a list of hundreds of concepts in one go. Relations 
addition is not included in OntoFast, as the aim of this program development is to have an 
enriched ontology with synonyms, references, and definition. It was not meant to provide 
relations of the concepts as mapping relations is a trivial scenario for any ontology editing 
program e.g. Protégé. 
5.1.4 OntoFast: 
In this section we discuss about an application, OntoFast [208], which allows to speed up the 
standard procedure of ontology development and metadata integration. Usually these processes 
take anywhere between many months to a couple of years and involves many people. For 
example, Protein-Ligand Interaction Ontology (PLIO) [264] was developed in 18 months, 
Multiple Sclerosis Ontology (MSO) [28] was developed in one year and Gene Ontology (GO) 
took many years and is still being updated. One of the main hurdles while developing MSO was 
the difficulty of introducing new concepts into the Protégé user interface. This task proved to be 
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time consuming and labor intensive. Since the ontology engineers are specialists in their domain 
and they may develop ontologies only for their specific needs, they are usually not experts in 
ontology development work. This lack of practice often slows down the progression of the work 
and forces them to do repetitive tasks which can be automated easily. OntoFast solves this 
problem by providing an easy-to-use and convenient interface which can prevent domain experts 
wasting the precious time. More than one synonym and reference can be given in different lines 
by copy paste, making it more convenient for information retrieval systems to broaden the 
coverage of the ontology. Different options allow users to embed definitions, synonyms and 
references of the ontology via an easy-to-use graphic user interface. Since ontologies can be 
designed with different hierarchies and different application scenarios which vary from domain 
to domain and from task to task, hierarchical feature were not added into it. The output of the 
program can be easily opened with any standard ontology editor like Protégé. Then the hierarchy 
can be customized by simple drag and drop, according to the user’s specific needs. Figure 5.3 
shows the interface of the application with different options, a button to load a Text file of 
concepts, a field to add definition, and text boxes for synonyms and references.  
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Figure 5.3: OntoFast interface and description of various options 1) Load button for loading a list of concepts from a txt 
file. 2) Concepts list which shows concepts loaded from a txt file. A concept can be selected by clicking on it. The selected 
concept will be highlighted. 3), 4) and 5) fields are for defining basic properties of the selected concept. Synonyms and 
References fields can take more than one value. 
 
In earlier section of the current chapter, it has been shown that metadata associated with 
biomedical concepts can be retrieved automatically from UMLS by using KNIME workflow 
[29]. In the following section, the approach to build an ontology quickly using OntoFast, from 
the metadata retrieved, will be discussed.  
Importing concepts in OntoFast is very easy, since the list of concepts can be imported by 
clicking on the “Load new Txt” button. All of the concepts of a prospective ontology can be 
given in the form of a list in a text file (.txt). Fields in the text file should be separated by 
carriage return commands. The application reads each new line as a new concept and generates 
the list of concepts that is visualized in the “Declarations” text box. The associated metadata can 
1 
2 
3 
4 5 
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be then added by selecting a concept in the list. Selected concepts will be highlighted. Just after 
importing the list of declarations, the application asks to choose the output .xml file, which can 
be used in Protégé or in any other ontology editing application. From this moment, the user will 
not need to take care of manually saving the output .xml file, since the application will execute 
automatic saving every time a different concept is selected, as well as on exit.  
Metadata can be easily associated with the imported concepts by selecting a concept and 
providing the associated details in relative fields. The main attributes required for the ontology 
were definitions, synonyms and references; thus there are different text boxes given to 
incorporate the same attributes. As the goal was to speed up the initial step in the development of 
new ontologies, each of the boxes can accommodate copy/paste to quickly populate the 
ontology. In addition, more than one synonym and reference can be given in different lines. 
Finally, the hierarchy of the ontology can be arranged later on by the user in Protégé, since such 
an operation can be carried out very quickly within it. OntoFast can be downloaded from 
http://www.francescopappalardo.net/ontofast.zip. 
After retrieving the data from a biomedical database and developing the disease ontology, the 
next step was to gather publically available data e.g. Clinical trials etc. An innovative approach 
has been used to download a clean dataset from public source.  
5.1.5 Corpus generation from web to analysis the content and applying NLP tools: 
The approach described here allows easy and efficient storing of web pages, as well as generates 
a clean corpus of relevant data. The requirement of this approach is as follows. 
The corpus generation methodology was developed to facilitate the web mining and make it 
easier to get a clean corpus in no time. There are many web mining tools dedicated to perform 
this job with different levels of complexity, including depth of the weblinks as well as parsing in 
real time while crawling the web. These tools, however, do not have a straightforward and 
simple GUI to perform the simple task of gathering a clean dataset. Nutch [265], Websphinx 
[266], and openwebspider [267] are some of the popular tools available to do this job. That said, 
extracting and getting corpus straight from web-links is such a basic task which requires neither 
such advanced tools nor the skills to operate them. Besides, the output of these tools may contain 
irrelevant files & folders and a not-so-clean dataset. In addition, the requirement to have a clean 
corpus pushed us to have a methodology which could be used on any site with minimal 
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modification and contained the highest percentage of content purity. The other tools mentioned 
above crawl the web, thus users have limited control on the content which is downloaded, 
gathered, extracted, or retrieved. They do not offer the best option to have a clean dataset. Our 
methodology retrieves a clean dataset from any given website (with a few limitations) and the 
resulting dataset would only contain the data required by the user. The dataset then could be 
further used to perform different linguistic tasks to get the best results.  
Use case:  Here we present our use case with the website www.LinkedCT.org and how we 
processed the site with our methodology, resulting in a clean dataset of clinical trials specific for 
RRMS. LinkedCT is a semantically processed site of www.clinicaltrials.gov (Figure 5.4). 
 
 
Figure 5.4: Home page of LinkedCT [268], clinical trials are categorized by different headers. 
 
LinkedCT provides categorization of clinical trials based on clinical trials ID, Interventions, 
conditions, locations, MeSH terms, and reference of the publications. This classification makes it 
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easier to find any clinical trial from its metadata. There were approximately 1,86,004 processed 
clinical trials at the time of this writing (Figure 5.5).  
 
Figure 5.5: Total number of clinical trials in Linked CT.org. 
 
The requirement of the work is to download all the clinical trials associated with a particular 
disease subtype (RRMS) and those clinical trials were stored beneath four variations of disease 
name (Multiple sclerosis Relapsing-Remitting, Relapsing-remitting Multiple Sclerosis, Relapse-
Remitting Multiple Sclerosis, and Relapsing Remitting Multiple Sclerosis). The actual data files 
(RDFs) were stored beneath three html pages of each of the disease name label (Figure 5.6(1)). 
We stored each of the page under disease name as html file and then merge them together to 
have all the NCT trial numbers on one html page (though they were stored with the variations of 
disease name on the website) (Figure 5.6(2)). It was found that the pattern of RDF data file URL 
and the page where it contains the link of the RDF data file (Figure 5.6(3)) doesn’t differ much 
and there is a similar pattern for each RDF data file URL (Figure 5.6(4))  associated with the 
webpage link. Further, we extracted all the links by using LinkGopher from the merged NCT 
trial numbers page and then observed at the patterns of RDF data file URLs and html pages 
URLs. After finding out the pattern, keywords have been replaced with the one which was 
associated with RDF data files and then all the RDF files were downloaded by using 
DownThemALL. 
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Figure 5.6: The layers of web pages and actual dataset require for the work (marked with number 4 and labeled with 
RDF).  
 
5.1.6 SBML2SMW, Transforming Systems Biology knowledge into MediaWiki Pages: 
One of the important aspects of our work was to preserve and reuse the knowledge extracted 
from different sources so it can be used for Systems biology modeling work. For this, 
MediaWiki software was chosen as the central component of the system due to its 
interoperability and reliability. In addition, there are many off-the-shelf plug-ins available which 
extend the functionality of MediaWiki. However, there was no Systems biology connection to 
Semantic MediaWiki and to fill this gap; we aimed to have a framework which would have 
different capabilities (discussed below in details). 
5.1.6.1 User Requirements: Interface and infrastructure:  
An easy-to-use graphical user interface was a prerequisite, since the primary users of the system 
would be biologists. Due to the collaborative work and enriching the knowledge base, it was 
important that each user's activity could be appropriately monitored and an administrator must be 
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able to trace and if needed, revert individual changes. Data retrieval has to be easy and all the 
associated knowledge with any particular entity should be available with a few clicks. 
Interoperability with other systems via open APIs is also required. Portability of the back-end 
must not be an issue and it should work on any standard Windows/Linux servers and on any 
portable computing device (from PC to Mac and Tablets). 
5.1.6.2 Modeling software as front end:  
The modeling software must support SBML and the graphical user interface should be rich 
enough to represent biochemical networks and health related issues (e.g. adverse drug reactions 
and drug-drug interactions). It should be able to connect with external databases and have robust 
capabilities of network analysis and quantitative modeling.  
5.1.6.3 Knowledge base as back end:  
The semantics of the knowledge base should be explicit, completely ontologically annotated, and 
interoperable with different knowledge sources. The knowledge base must be stable and have a 
proven record of flexibility and scalability. A state-of-the art and open source solution is needed. 
After thorough research and market analysis, it has been concluded that all requirements 
described above could be addressed by combination of two publically available tools, 
CellDesigner and Semantic MediaWiki (SMW). The development of a "semantic glue" (to 
bridge these two technologies) is the best option available to solve the issue. Hereafter the 
reasons for the choice in the context of the requirements have been described. 
5.1.6.4 Evaluation of off-the-shelf technologies: 
Several implementations of wiki exist in biology (e.g. WikiGenes [269], WikiProteins [270], and 
WikiPathways [271], unfortunately none of them matched the requirements. For example, 
WikiPathways enables community curation; however, it does not enable dynamically importing 
connections as found in other pathways stored in WikiPathways, since the pathways are stored as 
"In-silos" (each separates from the others). Another example is the Payao system [239], which 
enables a more systematic, community-based annotation and curation with SBML and SBGN 
compliance; but they are "network centric" and thus do not share the relations between pathways. 
It has also been shown [272] that Semantic MediaWiki has the capabilities to write labeled links 
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to create RDF triples. It is very simple to use and can serve as a useful tool for collaborative 
editing according to simple RDF statements, which is also appropriate for biology. More 
recently, the project HALO has shown [273] that low-cost highly-scalable modeling of basic 
scientific knowledge in health science could be appropriately handled with Semantic MediaWiki 
and a further added biology-friendly extension (SMW+). Therefore, MediaWiki and the SMW 
extension have been chosen as the core technology for the Systems biology knowledgebase. In 
order to enable CellDesigner to access (in read/write mode) the SMW, the SBML2SMW plug-in 
[274] has been used. That plug-in has been developed independently and at the same time as the 
PathwayAccess [275]. It does not exploit their API, but in order to bridge the internal data 
representation of CellDesigner and the SMW, it exploits a minimal ontology and an ontology 
mapping service. This makes it on-the-fly compatible with any RDF environment e.g. IWB 
[276]. The current infrastructure enables a variety of scenarios, including: collaborative 
knowledge acquisition and hypothesis generation, automatic knowledge update via text mining, 
knowledge condensation (e.g. using CellDesigner and PathwayAccess plug-ins), and large scale 
knowledge reasoning (e.g. exposing the content with a SPARQL entry point).  
5.1.6.5 The Integrated framework and Solution: CellDesigner: Advanced front-end for 
systems biology domain experts:  
The features of CellDesigner and its various functionalities have been discussed in chapter 4. 
5.1.6.6 SMW: Front-end for occasional users and powerful knowledge storage:  
SMW is a free extension of MediaWiki that adds semantic annotations, therefore allowing the 
wiki to function as a collaborative database with semantically tagged content. MediaWiki has a 
large variety of extensions which make it directly pluggable into the semantic web as a SPARQL 
entry point and as a linked data server. In view of the very solid semantic foundation of SMW, 
OWL DL (Web Ontology Language, Description logic), and its proven robust wiki structure 
relying on MediaWiki (the software behind Wikipedia.org), it has been decided to use it as the 
core technology. The RDF export capabilities of SMW allow the seamless transfer of its content 
to other powerful semantic stores. To use SMW as core technology, the only problem to be 
solved was to create a bidirectional bridge between SMW and CellDesigner.  
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5.1.6.7 CellDesigner - SMW integration:  
To integrate these two different platforms; a plug-in of CellDesigner SBML2SMW has been 
developed, which transforms all the knowledge curated in CellDesigner model into Mediawiki 
knowledge base. This facilitates:   
• Acquisition of semantically enriched and scattered biomedical knowledge from different 
sources (i.e. DBGET, SGD, iHOP, Genome Network Platform, PubMed, Entrez Gene, 
SABIO-RK) as shown in figure 5.7. 
• Sharing and reusing knowledge networks in the context of biomedical hypotheses 
generation 
 
Figure 5.7: The overall workflow of the system. CellDesigner retrieves data from different databases and with the tool 
discussed (SBML2SMW), it can convert the data into web pages, where a user can read it through web browser or an 
expert can get in-depth knowledge from the CellDesigner application. External queries can also be executed by using 
different applications like LarkC etc. 
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CellDesigner imports data from different knowledge sources and with the SBML2SMW plug-in, 
it can convert the data into semantic wiki pages. At this point, an occasional user can view it, 
comment on it, and edit it through a web browser; an expert can perform quantitative modeling 
using SBW or other tools e.g. Copasi [277] etc. External queries can be executed by using 
different applications like LarkC [278]. The semantic knowledge base can be automatically 
enriched by different text mining tools (e.g. ProMiner, Luxid, GATE, BioNotate, I2E, 
NCBOAnnotator, etc.), given that these tools are able to generate RDF using a common set of 
ontologies. In addition to the SBML2SMW plug-in, a "translation server" has to be deployed on 
the client or on the server, which automatically maps the curated models between the core 
ontologies used in CellDesigner and the SMW model. This ontology mapping has been modeled 
in OWL DL for coherence with the SMW model. It was intentionally kept small and concise, 
covering only the required aspects of SBML models, and can be easily extended. A graphical 
representation of the resulting ontology is shown in Figure 5.8. 
 
Figure 5.8: A mapping ontology between CellDesigner models and Semantic MediaWiki. 
 
After all the foundation work of information representation, in the next section, we will discuss 
about the approaches which have been used to model MS.   
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5.2 Modeling of MS disease: 
5.2.1 Molecular interaction map of MS: 
The molecular interaction map of MS was developed to reveal the underlying mechanisms of the 
disease by laying interacting molecules and pathways associated with them. A molecular 
interaction map reveals the mechanisms of different pathways; and by looking at it, one can 
instantly become familiar with the mechanism of different drugs and their interactions with other 
molecules. The clinical trials overlay on molecular interaction map also provides a means to see 
the clinical phenotype caused by molecular interactions. DrugBank data provides a detailed 
description about drug behavior. The MS molecular interaction map was developed after the 
evaluation of different commercial suites i.e. Genego, IPA, and Biobase. None of those software 
suites provided the function of sentence support underneath the edge. The Miriam section of 
CellDesigner was extended to accommodate and store the textual support of the relation.  
5.2.1.1 Disease model development and validation: 
The model was split into 3 parts due to its large size, as it contains ~650 nodes and ~900 
connections. Most of the nodes are proteins or bio-molecules and then phenotypes associated 
with them. There are also genes which show significant association with the disease. The map 
also contains drugs acting on different molecules, as clinical trials data was overlaid after the 
literature sources.  
There were five interaction types, represented as lines with arrowheads and other shapes. 
Different shapes of links represent different interaction types e.g. inhibition, activation, 
increment, decrement and modulation. The legend set of edges was adopted due to the limited 
expressiveness of CellDesigner edges. For example, the default legend set in CellDesigner can 
assign an increment or decrement in a process but a protein expression cannot be changed 
(increment or decrement) by the actions of other biological molecules. However, in human body 
it does happen. To keep the model simple, a new legend set has been introduced which 
represents the actions of biological molecules on other set of molecules either increment or 
decrement. Under each edge, the supporting sentence was embedded with the PubMed ID of the 
scientific paper from which it was taken (Figure 5.9). 
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Figure 5.9: The supported sentence extracted from scientific literature, after manual reading, and PubMed ID stored 
under each edge in the molecular interaction map. 
 
The following are the seven types of entities: genes, proteins, receptors, drugs, cells, phenotypes, 
and degradation. Aside from degradation and phenotype, all entities have their UMLS unique 
identifier stored within the interaction map. The names of the molecules were taken as 
mentioned in the literature, but later they were mapped as proper UMLS identifiers by searching 
each of them in UMLS database. 
 
 
Figure 5.10: CellDesigner entities legends and interactions legends used to model MS map.  
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Following Knowledge set was embedded under each entity and Interaction: 
1) UMLS CUI (Entities) 
2) Sentences in Miriam (Interactions) 
3) PubMed ID (Interactions) 
The interaction map was one of the first of its kind, as it was developed by reading literature 
manually, and the support of each edge is available within the map. The map was also 
transformed into a complete wiki running internally with the help of the CellDesigner plug-in 
SBML2SMW [274]. In addition, the knowledge within the map was linked by LinkedOpenData 
consortium datasets by using an external application “Information workbench” [276]. This 
allowed us to dig deeper into each of the nodes and edges in real-time with transient retrieval of 
information by using federated queries to various datasets. Figure 5.11 gives a glimpse of the 
molecular interaction map of MS, since the map was large enough thus only a portion of map is 
shown here. The MS map has been published at Payao website 
[http://sblab.celldesigner.org/Payao10/bin/]. 
 
1
0
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Figure 5.11 : One part of the MS Model. Model was split into three parts due to its large size. 
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5.2.1.2 Example usage of SBML2SMW with CellDesigner Model:  
The architecture described in the previous sections opens up semantic web technologies to new 
user groups and applications. When a biologist models complex facts in CellDesigner, he or she 
can easily populate SMW with the newly discovered knowledge. Users can edit information 
directly in the wiki without the need of CellDesigner. Advanced users can also run complex 
SPARQL queries. For example, an expert user could easily find all reactions having a generic 
protein marked as hypothetical and catalyzed by catalyst X, by running one SPARQL query. The 
complexity of the query can be extended by combining this knowledge with other knowledge 
sources i.e. LinkedOpenData [279] , and using more powerful platforms e.g. LARKC [278]. 
Evaluation: The system has been used for the last 20 months, and it is smooth and stable. 
Initially, the system was capable of retrieving entities but not relations. A newer version of the 
plug-in (SBML2SMW) was developed with the feature of relations retrieval among the entities 
as well as all the data associated with them, such as supported sentences for the relations and 
PMID of the papers from where the supported sentence was taken. In addition, under each entity 
there are the UMLS concepts’ identifiers which can also be retrieved from the SMW pages. The 
system is being used by our biologist colleagues at different geographical locations without any 
issue. Figure 5.12 shows the entity before the retrieval of the previously stored knowledge, and 
after retrieval, accomplished by selecting the entity (ProteinA) and pressing the "Load" button 
from the SBML2SMW popup box. All the associated knowledge with ProteinA will be retrieved 
from the backend SMW and displayed in CellDesigner. 
 
 
Figure 5.12: Retrieval of knowledge associated with an entity by using SBML2SMW plug-in. The newly added entities 
were stored previously by using store option of SBML2SMW plug-in into backend Semantic MediaWiki. 
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Before retrieval, a model has to be stored by using SBML2SMW plug-in store feature and 
SBML2SMW transformed this knowledge into backend SMW. After the transformation of the 
model, the knowledge curated within the model can be seen as wiki pages (Figure 5.13). 
 
              
Figure 5.13: MediaWiki pages of stored entity (left) and interaction (right) of MS map. On reaction page, type of reaction, 
name of product and reactant can be seen.  
 
5.2.1.3 Overlaying Clinical Trials and DrugBank data: 
Clinical trials and DrugBank data was overlaid on the interaction map to incorporate the 
phenotypical findings in the literature as well as in the clinical trials. DrugBank data was added 
to have drugs mode of action and molecules they target. The clincial dataset used was from 
NMSS, as described in the methodology section. The integration helped us to show a broader 
aspect of a disease by combining different streams of knowledge. In addition to clincial data, 
drugs’ information was taken from the DrugBank RDF repository to run complex queries. The 
final integrated map contained molecular entities from literature, phenotypes from clinical trials 
and drug knowledge from DrugBank.To the author’s knowledge, this is the first molecular 
interaction map to use these different streams of knowledge to represent a neurodegnerative 
disease.  
In addition to overlaying the DrugBank data, we also looked at the modes of action and possible 
mechanisms of the drugs and created a chart based on the most frequently occuring disease 
mechanisms associated with MS disease in the clinical trial dataset. Figure 5.14 shows that most 
of the drugs being tested interact with a mechanism involving the immune system in order to 
treat the disease. This exercise has been done as some of the drugs for the treatment of MS have 
unknown functionalities, and eventhough a wide body of literature supports the notion that MS is 
110 
 
primarily a disease of the immune system, there is still a disagreement within the scientific 
community over this theory. 
1
1
1
 
 
 
Figure 5.14: 15 top ranked mode of action of MS approved drugs, after processing clinical data taken from NMSS [244]. 
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After developing the molecular interaction map of MS, the next task was to discover the specific 
pathways behind each of the disease subtypes in chronological order. The segregated pathways 
may involve to specific disease patterns thus we hypothesized that drugs targeting certain 
pathways may be combined to treat patients who are non-responders to some therapeutic agents. 
Combination therapy in MS is not a new topic, several papers [280–282] have been discussed 
this option to cure the disease but unfortunately the scope appears limited. Few studies were also 
carried out to find the efficacy of combinatorial therapies and one of them showed that IFN-Beta 
1a and Glatiramer Acetate combination is not efficacious than IFN-Beta 1a alone [283]. In the 
following section, the pathways involved in different disease subtypes and the best possible 
combinatorial therapies with the help of pathways involved in different disease subtypes will be 
discussed. 
5.2.2 Time series of MS disease progression and combinatorial therapy: 
In this section our approaches to find out key elements behind each of MS disease subtype in 
time dependent manner have been described. In addition to finding disease mechanisms specific 
to a disease subtype, the possibility to use combinatorial therapy as a solution for non-responders 
will be explored by targeting pathways specific to the disease subtypes. To work with the stages 
of MS disease progression, the disease was segregated based on the biomarkers found in specific 
disease subtype and also the interacting molecules of the therapeutic agents. Following two 
different approaches have been used and outputs of both were compared to reveal the pathways 
which were commonly found or specific to a certain disease subtype: 
• Literature based discovery 
• Drug network based discovery 
We speculated that if the outputs of both approaches are identical then it would confirm that the 
drugs were interacting with the same molecules perturbed in the disease subtype. On the 
contrary, if they are different, then a combination therapy can be proposed.  
5.2.2.1 Literature based discovery: 
In the literature-based approach, we collected the documented biomarkers associated with each 
stage of the disease by the methods described in previous chapter. For clarity, the workflow of 
the approach has been given: 
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Figure 5.15: Overall workflow of the approach for the literature-based discovery. 
 
Figure 5.16 shows the relevant biomarkers mentioned with each disease subtype, mapped as their 
association was described in the literature.  
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Figure 5.16: Different biomarkers grouped by type and associated with different disease subtypes. The total number of 
biomarkers is not the sum of rows, as some biomarkers were played more than one role in the disease. 
 
There were many structural biomarkers specific for lesion types and their location, but we only 
considered molecular biomarkers with an HGNC identifier. We did not combine all the different 
type of biomarkers (Predictive, Prognostive and Diagnostive) as that would have been too many 
molecules and pathways. In addition, Pharmacovigilance biomarkers have not been used further 
as the main interest of the work was to discover disease mechanisms. 
Only one biomarker was found to have a predictive role in the disease subtype PPMS, and only 
three in the disease subtype SPMS. This could be a reason why it is difficult to treat, slow down 
or even predict disease progression in advanced stages as well as not having a drug for PPMS so 
far. 
Figure 5.17 shows the pathways mapped with predictive type biomarkers in disease subtype 
RRMS. Using the same method, all the relevant pathways have been mapped to all the 
biomarkers of disease subtypes e.g. CIS, RRMS (Predictive, Prognostive, Diagnostive), PPMS 
(Diagnostive), SPMS (Predictive, Diagnostive). 
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Figure 5.17: Pathways retrieved after uploading list of RRMS Predictive Biomarkers into IPA. 
 
5.2.2.2 Drug network based discovery: 
Using a drug network-based approach, we aimed to discover chronological events occurrence in 
MS disease based on drugs prescribed. Following FDA-approved MS drugs have been selected 
and their molecular networks were constructed. The networks were mapped to pathways and top 
pathways were filtered out (Figure 5.18). The selection of drugs was made based on disease’s 
state for which they are most commonly prescribed. 
1. Interferon beta 1a  
2. Interferon beta 1b 
3. Glatiramer Acetate 
4. Fingolimod 
5. Natalizumab 
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6. Mitoxantrone 
7. Methylprednisolone 
8. Dimethyl Fumarate 
9. Teriflunomide 
The workflow of the approach to construct pathways linked with drugs is as follows: 
 
 
Figure 5.18: Overall workflow of the method for drug network based discovery. 
 
The drugs were segregated based on prescription pattern and therapeutic course e.g.1st line 
therapy and 2nd line therapy, as shown in figure 5.19. The 3rd line therapy is considered as 
combination therapy, while the 4th line therapy and final treatment option is a bone marrow 
transplant. The idea of segregation is to see if the drugs are perturbing the pathways intended.  
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Figure 5.19: Two different disease segregation approaches based on therapies given at different stages and therapies 
considered as in chronological order were applied. 
 
The drugs’ networks were constructed with the knowledge available in IPA and then canonical 
pathways were mapped on the networks. The pathways were selected based on the maximum 
matches of molecules within the drug network; that is, the topmost pathway would be the one 
where the maximum number of molecules played key role in it. So theoretically, one could get 
all the pathways involved in a certain disease subtype by constructing the network of drugs 
prescribed (to treat or suppress the disease condition) and overlaying it with the canonical 
pathways. Figure 5.20 shows the details of the approach. 
 
 
Figure 5.20: Drug network and pathway overlay: (A) Drug network retrieved from IPA knowledge base (B) Top 
associated canoncial pathways mapped with drug network. 
(A) (B) 
(A) 
(B) 
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Now, we have disease specific pathways (for each disease subtype) constructed from biomarkers 
and pathways constructed from drug networks. As the next step, a speculation was made to see 
whether or not there is a match between the two streams of knowledge. To test the speculation, 
comparisons of discovered pathways were performed. Figure 5.21 shows the simplified version 
of our comparison approach as we wanted to discover how many pathway matches there are, if 
any, and what role they play in different disease states.  
 
 
Figure 5.21: Summary of the question we were interested to look into. 
 
Top 20 associated pathways of drugs and disease subtypes have been chosen to find out which 
drugs have an interaction role in any of the disease pathways. The early stage disease pathways 
(associated with CIS & RRMS) were mostly perturbed by Interferon beta 1a and 1b, while 
Teriflunomide and Mitoxantrone were more frequently associated with the severe disease 
subtypes e.g. SPMS. In accordance with the established knowledge, it has been confirmed the 
chronological pattern of disease segregation based on therapeutic intervention. In addition to that 
it has also been found that combinatorial therapy could play a significant role to treat patients 
who are non-responders to certain drugs. The severe disease subtype pathways can be targeted 
by combining more than one drug.  The approach is novel and unique as this is the first time to 
the author’s knowledge that two established knowledge sets were used to discover the pathways 
responsible for a disease state.  
Table 5.3 shows the number of pathways perturbed by different drugs and in different disease 
subtypes.  
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IFN - 
Beta 
1a 
IFN - 
Beta 
1b 
Glatiramer 
Acetate 
Natalizumab Fingolimod Mitoxantrone Teriflunomide Dimethyl 
Fumarate 
Methyl- 
prednisolone 
CIS 8 7 5 1 4 8 5 7 4 
RRMS_ 
Predictive 
10 13 8 1 1 8 4 4 3 
RRMS_ 
Prognostive 
7 5 4 1 1 5 1 5 3 
RRMS_ 
Diagnostive 
9 11 9 2 1 11 7 4 1 
PPMS_ 
Diagnostive 
9 9 8 0 1 9 5 5 3 
SPMS_ 
Predictive 
6 4 5 3 2 6 7 3 2 
SPMS_ 
Diagnostive 
7 6 10 3 2 8 9 5 4 
Table 5.3: Pathways involved in different disease subtypes and drugs acting on those. 
 
As discussed above that a study who looked at the combination therapy of IFN-Beta 1a and 
Glatiramer Acetate failed to prove that combination therapy is more efficacious than IFN-Beta 
1a alone [283]. With the help of our work, we were able to explore that one of the possible 
reasons for unsuccessful study was that both of the drugs IFN-Beta 1a and Glatiramer Acetate 
interacted with similar pathways. 5 out of 8 pathways interacted by Glatiramer Acetate in disease 
subtype RRMS (mapped to biomarker type predictive) were also interacted by IFN-b1a. This 
shows that the drugs’ mode of action was not non-overlapping (Figure 5.22). Figure 5.22 also 
shows that there are some pathways which are not interacted by some of the drugs and 
combining therapies based on those may yield beneficial outcome. However, experimental 
studies are needed to validate the findings.  
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Figure 5.22: Pathways mapped to biomarkers found with RRMS Predictive type and the drugs interaction with the pathways. 5 out of 8 Pathways interacted by 
Glatiramer Acetate are same as IFN-b1a. The likelihood to have a effacacious combination therapy with those therapeutic agents is less than combining IFN-b1b and 
Teriflunomide. 
Red filled  circles show the not interacting pathways by IFN-b1b. 1 shows the pathways interacted by drugs. Red boxes show pathways of IFN-Beta 1a and Glatiramer 
Acetate. 
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Figure 5.23 shows the chart of pathways being interacted by drugs in different disease subtypes. 
Please note that disease subtype pathways were mapped according to their relevant biomarkers, 
the name corresponds to the same. 
 
 
Figure 5.23: Disease subtype pathways being interacted by different drugs. Since the disease subtypes were segregated 
based on the associated biomarkers types, the pathways name corresponds to the same. IFN-Beta 1b interacts with the 
most number of pathways (with biomarker Predictive) in RRMS.  
 
As a next step, all pathways of a disease subtype have been merged, resulting in pathways for 
RRMS instead of RRMS Predictive, RRMS Prognostive and RRMS Diagnostive. We assigned a 
value of one if a pathway played a role in only one stage of the disease (i.e. Diagnostive). If a 
pathway was found in all three roles of disease subtype RRMS, then it would receive a value of 
three. Only pathways which occurred more than once in any subtype of disease have been 
selected. Table 5.4 shows the pathways ranked according to their occurrences in the different 
disease subtypes. Some unique pathways of disease subtypes were also found e.g. IL-12 
signaling pathway has a role only in the disease subtype RRMS; similarly, atherosclerosis 
signaling pathway has been shown in association with SPMS. 
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Pathways RRMS PPMS SPMS 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 3 
 
2 
Glucocorticoid Receptor Signaling 3 1 2 
Dendritic Cell Maturation 3 1 2 
T Helper Cell Differentiation 3 1 
 
IL-12 Signaling and Production in Macrophages 2 
  
Crosstalk between Dendritic Cells and Natural Killer Cells 2 1 
 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 2 
  
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 2 1 
 
HMGB1 Signaling 2 
  
Colorectal Cancer Metastasis Signaling 2 1 
 
Type I Diabetes Mellitus Signaling 2 1 
 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 2 1 2 
Role of Cytokines in Mediating Communication between Immune Cells 2 
  
Hepatic Cholestasis 2 
  
Communication between Innate and Adaptive Immune Cells 2 1 
 
Granulocyte Adhesion and Diapedesis 2 
  
IL-6 Signaling 2 2 
 
Leukocyte Extravasation Signaling 
  
2 
Agranulocyte Adhesion and Diapedesis 
  
2 
Atherosclerosis Signaling 
  
2 
Table 5.4: Pathways involved in different disease subtypes, only pathways which occurred more than once are shown 
here. Numbers here represent whether the same pathway is involved in all different types of biomarkers role (Predictive, 
Prognostive and Diagnostive). 
 
In addition to the above mentioned pathways, we also looked at all pathways to reveal unique 
pathways specific to a disease subtype. Figures 5.24 and 5.25 show different pathways involved 
in different disease subtypes, and those which are unique for certain disease subtype. For this, 
only presence in certain disease subtype were observed and not the frequency. For example, if 
IL-6 signaling pathway was found twice in RRMS (with Predictive and Prognostive biomarker 
type) it was only considered that it has a role in RRMS thus given value of one to show that it 
plays a role in RRMS.  
1
2
3
 
  
Figure 5.24: Pathways occurring in different disease subtypes. Only presence or absence was  recorded to show whether or not a pathway plays a role in disease subtype. 
1
2
4
 
  
Figure 5.25: Frequency of pathways occurring in disease. Pathways which have a score of three means that they play a role in all the three disease subtypes i.e. RRMS, 
PPMS, and SPMS. 
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Both the most and least frequently occurring pathways have been depicted, in order to show the 
importance of certain pathways. By looking at the chart, one could see the most frequently 
occurring pathways in the less severe and in the more severe disease subtypes. In addition, 
patterns of pathways could also give a speculation about the disease progression and type in 
patients.  
The next task was to develop a qualitative model of the disease where the relapsing remitting 
aspects of the disease can be simulated by using different factors involved. In next section, the 
result of modeling RRMS with Agent Based modeling is discussed. 
5.2.3 Agent based model of Treg-Teff interplay and its role in RRMS: The Model and 
Simulation: 
In this section, the results obtained from eight genetically predisposed, randomly chosen 
individuals have been presented. One aspect of this work is that it has been supposed that the 
appearance of a relapse and the presence of new unrecoverable neural damage are correlated 
[284], details are discussed in the previous chapter. The absence and presence of malfunctions of 
the Teff-Treg cross-balancing mechanisms at a local level have been reproduced. For simulating 
the absence of a local malfunction, it was supposed that both Teff and Treg populations had 
similar maximum duplication rates. In other words, we set the maximum duplication rate of 
Teff_dup and the duplication rate of Treg_pt to the same value, so both the cells’ populations 
have the same maximum duplication rates. It was further supposed that the breakdown of the 
cross regulation mechanism is due to a lower duplication rate pt of Treg. Table 5.5 shows the 
most important parameters used for the simulations.  
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Parameter Meaning 
treg_radius max visibility radius of Treg 
eff_dup max. duplication rate of Teff 
init_mye initial quantity of myelin per patch 
eat_mye quantity of myelin destroyed by Teff 
pt max. duplication rate of Treg 
patch_density max. no of entities per patch allowed to have duplication 
Teff_life Teff mean half-life 
Treg_life Treg mean half-life 
Table 5.5: Principal parameters of the MS agent based model. 
 
The model has been tested by simulating 100 randomly chosen virtual patients (data not shown) 
in both the ill and the healthy scenarios by setting [eff_dup = 0.1; pt = 0.025] and [eff_dup = 0.1; 
pt = 0.1], respectively. The total damage has been noted for both of the scenarios at the end of 
the experiments. Median values of the final total damage were 77,268 for the ill sample and 
5,357 for the healthy sample. Non-parametric Kolmogorov-Smirnov two samples goodness-of-fit 
test gave a maximum difference of D = 0.7500, (between the cumulative distributions) with a 
corresponding p-value of 0.000, thus suggesting that the two samples are unlikely to be drawn 
from the same distribution (i.e., they are statistically different).  
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Figure 5.26: The Conceptual Model of MS and the basis of the agent based model of MS. 
 
Figure 5.27 shows the behavior of Teff, Treg, and viruses vs. time for all the presented 
individuals in absence of malfunctions of the Teff-Treg cross-balancing mechanisms. The 
number of Teff (in red) has spikes at different time intervals in all plots. This indicates that in 
some cases, due to the stochasticity in the introduction of newborn cells, self-reactive Teff may 
initially escape from Treg control (blue lines) and can be activated due to mimicry, duplicate, 
and try to attack myelin. However, activated Treg are able to counterbalance Teff actions and 
maintain immune homeostasis.  
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Figure 5.27: Entity behaviors vs. time in healthy patients. The simulation is based on eight randomly-selected healthy 
virtual patients. Similar duplication rates have been assumed for both Treg and Teff. Simulation time is 5 years (18,250 
time-steps). Red lines represent activated Teff behaviors, blue lines represent activated Treg behaviors and green lines 
represent viruses’ behaviors. In this case, the number of Teff peaks is relatively small due to the action of regulatory 
mechanisms. This would result in lower probabilities of having unrecoverable damage. 
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In Figure 5.28, the behavior of Teff, Treg and viruses vs. time for all the individuals in the case 
of malfunctions of the Teff-Treg cross-balancing mechanisms has been shown. Similar to what 
has been observed in Figure 5.27, all plots show some spikes in the Teff behaviors (red lines). 
However, in this case, the spikes are more numerous and reach higher values than expected. This 
suggests that, due to the malfunction in the regulatory mechanisms, Teff can be easily activated 
and cause brain damage. In this case, Treg are not always able to contrast Teff actions and 
maintain homeostasis. 
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Figure 5.28: Entity behaviors vs. time in ill patients. The simulation is based on eight randomly-selected ill virtual 
patients. It was supposed that the breakdown of the cross regulation mechanism is due to a lower duplication rate pt of 
Treg. Simulation time is 5 years (18250 time-steps). Red lines represent activated Teff behaviors, blue lines represent 
activated Treg behaviors and green lines represent viruses’ behaviors. In this case, the number of Teff peaks is higher. 
Moreover, each peak reaches higher values with respect to healthy patients, thus indicating that higher numbers of self-
reactive Teff may entitle higher probabilities of having unrecoverable damage. 
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In figure 5.29, the levels of damage (recoverable, unrecoverable and total) for all the simulations 
have been shown. The presence of some spikes in the recoverable damage plots (blue lines) 
indicates that these correspond to the Teff spikes shown in figure 5.27. However, such damage is 
usually recovered, and at the end of this simulation almost no unrecoverable damage (red lines) 
remains.  
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Figure 5.29: Damage progression vs. time in healthy patients. The simulation is based on eight randomly-selected healthy 
virtual patients. Simulation time is 5 years (18250 time-steps). Red lines represent activated unrecoverable damage, blue 
lines represent recoverable damage and black lines represent total damage (recoverable + unrecoverable). Some spikes on 
the recoverable damage curves are present. However, such damage is usually recovered in healthy patients, as at the end 
of simulations the total damage is mostly zero. 
133 
 
 
In figure 5.30, the levels of damage are shown for all the simulations. The spikes in the 
recoverable damage plots (blue lines) are higher and bigger in number. It is also possible to 
observe the appearance of unrecoverable damage that indicates the appearance of MS plaques, 
and to see how the sum of both (total damage, black plots) mimics the typical relapsing-remitting 
dynamics observed in MS.  
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Figure 5.30: Damage progression vs. time in ill patients. The simulation is based on eight randomly-selected ill virtual 
patients. Simulation time is 5 years (18250 time-steps). Red lines represent activated unrecoverable damage, blue lines 
represent recoverable damage and black lines represent total damage (recoverable + unrecoverable). In this case it is 
possible to observe more frequent spikes in the recoverable damage curves. Furthermore, unrecoverable damage (that 
can be correlated with the appearing MS plaques) is also present. 
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Figure 5.31 presents the spatial plots at the end of every simulation (after 5 years) in healthy 
patients. The plots confirm the observations that came from Figure 5.27, as almost no black 
patches (which indicate the presence of some scarring or lesions) are present. 
 
 
Figure 5.31: Spatial plot at the end of the simulation in healthy patients. The figure gives a spatial representation of the 
simulated scenario (i.e. a small portion of brain tissues) at the end of the simulation for eight randomly-selected healthy 
virtual patients. Light green patches represent non-damaged areas. Dark green patches (see for example plot (c)) 
represent areas with recoverable damage. Black patches (see for example plot (b), yellow circle) represent areas with 
unrecoverable damage. Red dots represent activated Teff and blue dots represent activated Treg. Green dots represent 
viruses. White and black dots represent resting Teff and Treg, respectively. 
 
In figure 5.32, the presence of scarring can be seen, where the spatial plots for all individuals are 
presented at the end of 5 years. In all plots it is possible to see many black areas that indicate 
unrecoverable damage and thus the presence of lesions and scarring that may be correlated with 
relapses and the appearance of disability.  
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Figure 5.32: Spatial plot at the end of the simulation in ill patients. Figure gives a spatial representation of the simulated 
scenario (i.e. a small portion of brain tissues) at the end of the simulation for eight randomly-selected healthy virtual 
patients. Light green patches represent non-damaged areas. Dark green patches represent areas with recoverable 
damage. Black patches represent areas with unrecoverable damage. Red dots represent activated Teff and blue dots 
represent activated Treg. Green dots represent viruses. White and black dots represent resting Teff and Treg, 
respectively. 
 
We also observed that (data not shown), in some cases (for some seeds) a decrease in the Teff or 
an increase in Treg proliferation does not always indicate less severe relapses and, as a matter of 
fact, it could produce more severe relapses. This is mainly due to the stochasticity of the model. 
It may happen that the stochastic injection of new resting Teff may not be shortly followed by an 
equivalent injection of Treg, which would create a temporary disequilibrium between the two 
populations; this would result in some neural damage even in potentially healthy patients.  
The results presented here suggest that the presence of a genetic predisposition is not always a 
sufficient condition for developing the disease. Other conditions such as a breakdown of the 
mechanisms that regulate and allow peripheral tolerance should be involved. This has also been 
observed in [285]. In our case, we supposed that a malfunction of self-reactive regulatory T-cells 
caused by lower duplication rates was the cause. Of course, other conditions may be the cause of 
such a malfunction. 
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Moreover, it was also observed that in the simulations of ill patients, relapses mainly occurred in 
the first half of the simulation rather than in the second half (see Figure 5.30, plots (a),(c),(d) and 
(e)). This could be in line with clinical observations which showed that the relapse rate tends to 
decrease as the disease progresses [286,287]. 
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6 Conclusion and Outlook: 
*******************************************************************  
Drug discovery with the help of Systems biology is a modern approach, as the conventional 
means of drug discovery are not efficient for finding treatments for polygenic diseases and there 
is a large unmet medical need. Polygenic diseases affect many systems of the body, thus 
studying the root cause as well as the chronic nature of the disease progression is crucial to 
finding a cure. The diseases of the human brain are among the most complicated polygenic 
diseases, which is unsurprising given that it is ranked as the most complicated object in the 
known universe. Unlike other organs, it is not directly accessible for observation e.g. ears, eyes, 
nose or skin, and it never stops functioning throughout life as it plays a crucial role in nervous 
system. Since the organ and its diseases are so complex, a systematic view of the diseases could 
be considered as an appropriate approach to find therapeutic treatments. In addition, the 
emergence of new technologies in biomedicine and the availability of vast variety of datasets 
with different formats make it challenging to have a clear picture of biological mechanisms, 
unless an integrated approach is considered. Systems biology provides the tools and methods to 
unravel the mechanisms behind complex phenomena. 
Multiple sclerosis, being one of the most complex and expensive neurodegenerative diseases, has 
unmet medical needs due to its unknown etiology and varying pattern of progression. The 
disease affects mostly young people between 20-40 years of age and in an observable chronology 
renders patients disabled. To find the underlying disease mechanisms and biological phenomena, 
systems biological approaches have been used to discover the pathways involved in the disease 
and to seek a cure for the disease.  
The modeling of diseases has been recently gained popularity after the successful acceptance of 
type 1 diabetes metabolic simulator (T1DMS) by the FDA as a substitute for pre-clinical animal 
testing of new treatment strategies for type 1 diabetes mellitus [154]. In-silico models allow the 
changing of parameters fairly easily in order to affect the variations in outcomes. We developed 
models to simulate the disease conditions in-silico and foster drug discovery by analyzing those 
models. These models were developed with different approaches and mainly based on manually 
curated knowledge excerpted from scientific literature.  
The approach we used allowed us to systematically capture knowledge obscured in the literature 
and helped us to find unique patterns of disease foundation, its signatures and progress patterns. 
Besides disease modeling, a disease-specific ontology was developed to have a context-based 
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search of concepts and phenotypes associated with them. Further, the enrichment of the concepts 
with relevant Spanish terms made it possible to extract valuable knowledge from the Spanish 
dataset. The methodology to enrich ontologies with the synonyms from 23 languages has been 
derived and used in our work. A software program was also developed to ease ontology 
development with essential concepts integration so that a framework of information to 
knowledge has been projected. Information can be gathered about any specific topic or any 
specific disease with the guidance of the methodology described in our paper [30]. The concept 
synonyms can be retrieved from one of the largest repository of medical language or any 
MySQL database as described in our paper [29]. The translation of the ontology is also possible, 
as UMLS provides support for many languages. The software tool helps to integrate concepts’ 
synonyms and relevant information, and convert all into an ontology [208]. The framework not 
only develops de novo ontologies but can hypothetically enrich and translate any existing 
ontology. This answers our question of how to transform information into an integrated 
knowledge base. The following achievements of the thesis are given: 
- A methodology to extract biomedical information from publically available data 
as well as proprietary data (e.g. Clinical Trials or UMLS database), and transform it into 
a structured ontology; this includes the possibility to enrich and/or translate it into any of 
23 languages, thus broadening the ontology-based information extraction and coverage. 
- Knowledge-based models of multiple sclerosis in the form of molecular 
interaction maps, disease ontology and an agent based dynamic model. The disease 
ontology provided significant correlation between multiple sclerosis, showing relations 
with other diseases and its role in comorbidities. The model provided disease simulation; 
it has been shown that an agent-based model could simulate virtual patient symptoms of 
relapsing remitting multiple sclerosis and the protective role of vitamin D. A time pattern 
of disease progression has also been modeled, and it has been shown that different 
biomarkers and unique pathways are involved in different stages of disease with respect 
to time. In addition, drugs’ interactions were explored and molecules which interacted 
with more than one drug were investigated. The models developed can be helpful tools to 
find an appropriate drug candidate for the cure of the MS disease. 
-  A methodology and application to transform molecular interaction models or any 
SBML file into a Media wiki-based knowledge base. The application allows users to 
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connect a semantic knowledge base with internal and external databases and to enrich the 
models with information from any linked data platform.  
We have discovered novel pathways about each of the different disease subtypes and a future 
course of action would be to design drugs based on the molecules and biomarkers involved in the 
specific disease subtypes. Further, these molecules’ roles must be observed in human clinical 
trials. The current set of data is taken from published scientific literature where most of the 
findings were established on clinical animals; molecular interaction may vary in human subjects.  
The obvious next step after the modeling would have been the validation with clinical and 
experimental data; both are present at Merck and collaboration partners of Merck in the MS area; 
however the responsible people in the indication area have not been prepared to share the data 
thus approaches could not be validating in living organisms. The approaches we used can be 
applied to any disease and they open up a new prospect of discovering drugs. 
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